

JUNE 30, 2024

# FINANCIAL STATEMENTS



(A free translation of the original in Portuguese)

**Fleury S.A.**  
**Quarterly Information (ITR) at**  
**June 30, 2024**  
**and report on review of**  
**quarterly information**



(A free translation of the original in Portuguese)

## **Report on review of quarterly information**

To the Board of Directors and Stockholders  
Fleury S.A.

### **Introduction**

We have reviewed the accompanying parent company and consolidated interim accounting information of Fleury S.A. ("Company"), included in the Quarterly Information Form (ITR) for the quarter ended June 30, 2024, comprising the balance sheet at that date and the statements of income and, comprehensive income for the quarter and six-month period then ended, and the statements of changes in equity and cash flows for the six-month period then ended, and explanatory notes.

Management is responsible for the preparation of the parent company and consolidated interim accounting information in accordance with the accounting standard CPC 21, Interim Financial Reporting, of the Brazilian Accounting Pronouncements Committee (CPC) and International Accounting Standard (IAS) 34, Interim Financial Reporting issued by the International Accounting Standards Board (IASB) as well as the presentation of this information in accordance with the standards issued by the Brazilian Securities Commission (CVM), applicable to the preparation of the Quarterly Information (ITR). Our responsibility is to express a conclusion on this interim accounting information based on our review.

### **Scope of review**

We conducted our review in accordance with Brazilian and International Standards on Reviews of Interim Financial Information (NBC TR 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, and ISRE 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Brazilian and International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### **Conclusion**

Based on our review, nothing has come to our attention that causes us to believe that the accompanying parent company and consolidated interim accounting information included in the quarterly information referred to above has not been prepared, in all material respects, in accordance with CPC 21 and IAS 34 applicable to the preparation of the Quarterly Information, and presented in accordance with the standards issued by the CVM.




Fleury S.A.

## Other matters

### Statements of value added

The quarterly information referred to above includes the parent company and consolidated statements of value added for the six-month period ended June 30, 2024. These statements are the responsibility of the Company's management and are presented as supplementary information under IAS 34. These statements have been subjected to review procedures performed together with the review of the interim accounting information for the purpose of concluding whether they are reconciled with the interim accounting information and accounting records, as applicable, and if their form and content are in accordance with the criteria defined in the accounting standard CPC 09 - "Statement of Value Added". Based on our review, nothing has come to our attention that causes us to believe that these statements of value added have not been properly prepared, in all material respects, in accordance with the criteria established in this accounting standard, and consistent with the parent company and consolidated interim accounting information taken as a whole.

São Paulo, August 7, 2024

  
PricewaterhouseCoopers  
Auditores Independentes Ltda.  
CRC 2SP000160/O-5

DocuSigned by  
Marcelo Orlando  
Signed by: MARCELO O. ORLANDO/503684837  
CPF: 055094837  
Signing Time: 07 de agosto de 2024 | 15:37 BRT  
O: ICP-Brasil, OU: Secretaria da Receita Federal do Brasil - RFB  
C: BR  
Email: AC SERASA RFB v5  
ICP-Brasil

Marcelo Orlando  
Contador CRC 1SP217518/O-7

**Notes to the individual parent company and consolidated interim financial information as of June 30, 2024.**

**In thousands of reais (R\$), unless otherwise indicated.**

Individual parent company and consolidated financial statements

Balance sheet .....	5
Statement of income and of comprehensive income .....	6
Statement of changes in shareholders' equity .....	8
Statement of cash flows.....	9
Statement of added value .....	10

Notes to the individual parent company and consolidated financial statements as of June 30, 2024.

1. Operations .....	11
2. Presentation of the financial statements .....	12
3. Risk management .....	14
4. Securities.....	17
5. Accounts receivable.....	17
6. Inventories .....	18
7. Recoverable taxes.....	18
8. Other assets.....	19
9. Investments.....	19
10. Property, plant and equipment and intangible assets .....	20
11. Right-of-use .....	24
12. Suppliers .....	25
13. Financing .....	26
14. Debentures .....	26
15. Lease .....	28
16. Labor obligations .....	29
17. Obligations and tax installments .....	30
18. Accounts payable – Acquisition of companies.....	30
19. Other liabilities .....	31
20. Current and deferred income tax and social contribution .....	31
21. Provision for tax, labor and civil risks .....	33
22. Related parties .....	36
23. Shareholders' equity .....	38
24. Employee benefits.....	39
25. Revenue from rendering of services .....	40
26. Cost of services rendered.....	41
27. General and administrative expenses .....	41
28. Selling expenses.....	42
29. Other operating income (expenses), net .....	42
30. Financial income (expense) .....	43
31. Earnings per share - Parent Company.....	43
32. Information per business segment .....	44
33. Insurance coverage.....	44

See the accompanying notes to the financial statements.

**Balance sheet**

In thousands of reais – R\$

Assets	Note	Parent Company		Consolidated	
		06/30/2024	12/31/2023	06/30/2024	12/31/2023
<b>Current assets</b>					
Cash and cash equivalents		2,312	9,675	10,412	21,920
Securities	4	1,639,284	640,566	1,993,649	902,213
Accounts receivable	5	954,398	820,995	1,759,050	1,505,194
Inventories	6	60,160	56,718	139,551	134,929
Recoverable taxes	7	8,312	9,547	15,285	20,280
IRPJ and CSLL recoverable		109,987	110,885	169,898	162,486
Dividends receivable – Hermes Pardini		26,330	26,330	-	-
Other assets	8	29,966	26,299	79,884	56,535
<b>Total current</b>		<b>2,830,749</b>	<b>1,701,015</b>	<b>4,167,729</b>	<b>2,803,557</b>
Securities	4	43,130	34,319	122,887	133,482
Deferred income tax and social contribution	20	-	-	37,285	34,356
Judicial deposits	21	18,002	18,065	27,021	25,856
Accounts receivable	5	-	-	2,764	2,548
Other assets	8	27,500	29,333	45,715	47,557
<b>Total long-term assets</b>		<b>88,632</b>	<b>81,717</b>	<b>235,672</b>	<b>243,799</b>
Investments	9	4,401,637	4,205,703	93,409	81,519
Property, plant and equipment	10	800,221	830,714	1,320,192	1,348,492
Intangible assets	10	2,145,322	2,168,186	5,783,283	5,807,506
Right-of-use	11	783,538	852,554	1,202,109	1,295,095
<b>Total non-current</b>		<b>8,219,350</b>	<b>8,138,874</b>	<b>8,634,665</b>	<b>8,776,411</b>
<b>Total assets</b>		<b>11,050,099</b>	<b>9,839,889</b>	<b>12,802,394</b>	<b>11,579,968</b>
<b>Liabilities and shareholders' equity</b>					
<b>Current liabilities</b>					
Suppliers	12	319,490	303,060	676,475	620,413
Financing	13	14,509	10,162	19,513	12,473
Debentures	14	293,475	295,622	293,475	295,622
Lease	15	171,205	169,531	280,827	272,067
Labor obligations	16	220,425	226,505	352,951	338,989
Obligations and tax installments	17	34,853	28,522	75,872	63,016
Income tax and social contribution payable		15,574	1,971	33,411	17,567
Accounts payable - Acquisition of companies	18	1,821	4,529	15,876	31,097
Other liabilities	19	7,975	7,139	26,325	35,372
<b>Total current</b>		<b>1,079,327</b>	<b>1,047,041</b>	<b>1,774,725</b>	<b>1,686,616</b>
<b>Non-current liabilities</b>					
Financing	13	-	-	2,039	2,421
Debentures	14	3,497,881	2,499,057	3,497,881	2,499,057
Lease	15	712,326	780,785	1,061,775	1,159,409
Deferred income tax and social contribution	20	309,641	345,449	551,446	580,533
Provision for tax, labor and civil risks	21	11,745	5,882	167,701	161,339
Obligations and tax installments	17	1,412	1,475	3,594	12,929
Accounts payable - Acquisition of companies	18	80,919	76,731	312,188	366,576
Other liabilities	19	-	18	-	18
<b>Total non-current</b>		<b>4,613,924</b>	<b>3,709,397</b>	<b>5,596,624</b>	<b>4,782,282</b>
<b>Shareholders' equity</b>					
Capital	23.a	2,736,029	2,736,029	2,736,029	2,736,029
Capital reserve		1,915,527	1,915,451	1,915,527	1,915,451
Profit reserves		317,013	397,549	317,013	397,549
Treasury shares	23.d	(27,150)	(39,462)	(27,150)	(39,462)
Equity valuation adjustments		73,884	73,884	73,884	73,884
Income for the period from controlling shareholders		341,545	-	341,545	-
<b>Shareholders' equity of controlling shareholders</b>		<b>5,356,848</b>	<b>5,083,451</b>	<b>5,356,848</b>	<b>5,083,451</b>
Non-controlling interest		-	-	74,197	27,619
<b>Total shareholders' equity</b>		<b>5,356,848</b>	<b>5,083,451</b>	<b>5,431,045</b>	<b>5,111,070</b>
<b>Total liabilities and shareholders' equity</b>		<b>11,050,099</b>	<b>9,839,889</b>	<b>12,802,394</b>	<b>11,579,968</b>

See the accompanying notes to the financial statements.

**Statements of income and of comprehensive income**  
**Periods ended**  
**In thousands of reais - R\$, except income per share**

	Note	Parent Company			
		Three-month period June 30		Six-month period June 30	
		2024	2023	2024	2023
<b>Revenue from rendering of services</b>	25	<b>1,105,646</b>	<b>1,003,123</b>	<b>2,164,795</b>	<b>2,007,378</b>
Cost of services rendered	26	(760,587)	(709,375)	(1,468,831)	(1,407,923)
<b>Gross income</b>		<b>345,059</b>	<b>293,748</b>	<b>695,964</b>	<b>599,455</b>
Operating (expenses) income					
General and administrative	27	(106,614)	(167,946)	(216,242)	(279,969)
Selling expenses	28	(12,243)	(10,275)	(19,623)	(18,334)
Other operating income (expenses), net	29	(1,534)	451	(16,373)	(5,068)
Equity method and adjustment for realization at fair value	9	59,750	43,367	118,137	64,295
<b>Operating income before financial income (expense)</b>		<b>284,418</b>	<b>159,345</b>	<b>561,863</b>	<b>360,379</b>
Financial income	30	26,613	27,397	47,165	64,712
Financial expenses	30	(116,804)	(111,255)	(230,412)	(233,198)
<b>Financial income (expense)</b>		<b>(90,191)</b>	<b>(83,858)</b>	<b>(183,247)</b>	<b>(168,486)</b>
<b>Income before income tax and social contribution</b>		<b>194,227</b>	<b>75,487</b>	<b>378,616</b>	<b>191,893</b>
Income tax and social contribution					
Current	20	(46,632)	(20,913)	(72,879)	(39,985)
Deferred	20	25,991	19,853	35,808	16,372
<b>Net income for the period</b>		<b>173,586</b>	<b>74,427</b>	<b>341,545</b>	<b>168,280</b>
<b>Other comprehensive income:</b>					
Items that will be reclassified to income (loss) for the year in subsequent periods		-	-	-	-
Items that will not be reclassified to income (loss) for the year in subsequent periods		-	-	-	-
<b>Total comprehensive income (loss) for the period</b>		<b>173,586</b>	<b>74,427</b>	<b>341,545</b>	<b>168,280</b>
<b>Earnings per share attributable to Company's shareholders</b>					
Basic earnings per share (weighted average)	31	0.29	0.18	0.63	0.40
Diluted earnings per share (weighted average)	31	0.29	0.18	0.63	0.40

See the accompanying notes to the financial statements.



**Statements of income and of comprehensive income**  
**Periods ended**  
**In thousands of reais - R\$, except income per share**

	Note	Consolidated			
		Three-month period June 30		Six-month period June 30	
		2024	2023	2024	2023
<b>Revenue from rendering of services</b>	25	<b>1,978,202</b>	<b>1,659,541</b>	<b>3,882,650</b>	<b>2,896,364</b>
Cost of services rendered	26	(1,410,879)	(1,204,442)	(2,750,078)	(2,084,594)
<b>Gross income</b>		<b>567,323</b>	<b>455,099</b>	<b>1,132,572</b>	<b>811,770</b>
Operating (expenses) income					
General and administrative	27	(187,742)	(216,260)	(370,151)	(348,178)
Selling expenses	28	(49,585)	(38,444)	(84,301)	(47,522)
Other operating income (expenses), net	29	248	(2,893)	(20,297)	(4,050)
Equity in results of subsidiaries	9	(802)	255	(1,150)	255
<b>Operating income before financial income (expense)</b>		<b>329,442</b>	<b>197,757</b>	<b>656,673</b>	<b>412,275</b>
Financial income	30	39,213	58,879	75,679	103,886
Financial expenses	30	(140,543)	(158,389)	(287,284)	(292,935)
<b>Financial income (expense)</b>		<b>(101,330)</b>	<b>(99,510)</b>	<b>(211,605)</b>	<b>(189,049)</b>
<b>Income before income tax and social contribution</b>		<b>228,112</b>	<b>98,247</b>	<b>445,068</b>	<b>223,226</b>
Income tax and social contribution					
Current	20	(84,403)	(47,734)	(136,578)	(77,940)
Deferred	20	28,454	23,529	31,987	22,580
<b>Net income for the period</b>		<b>172,163</b>	<b>74,042</b>	<b>340,477</b>	<b>167,866</b>
<b>Attributable to the partners:</b>					
Controlling shareholders		173,586	74,427	341,545	168,280
Non-controlling shareholders		(1,423)	(385)	(1,068)	(414)
		<b>172,163</b>	<b>74,042</b>	<b>340,477</b>	<b>167,866</b>
<b>Other comprehensive income:</b>					
Items that will be reclassified to income (loss) for the year in subsequent periods		-	-	-	-
Items that will not be reclassified to income (loss) for the year in subsequent periods		-	-	-	-
<b>Total comprehensive income (loss) for the period</b>		<b>172,163</b>	<b>74,042</b>	<b>340,477</b>	<b>167,866</b>

See the accompanying notes to the financial statements.



**Statement of changes in shareholders' equity**  
**Periods ended**  
**In thousands of reais – R\$**

	Note	Capital			Profit reserves							Income for the period	Shareholders' equity of controlling shareholders	Non-controlling interest	Total shareholders' equity
		Capital	Share-issuance expenses	Net capital	Capital reserve	Investment reserve	Statutory reserve	Legal reserve	Retained earnings	Treasury shares	Equity valuation adjustments				
Balances at December 31, 2022		1,743,823	(26,601)	1,717,222	603,212	45,166	-	148,616	187,291	(19,971)	-	-	2,681,536	19,549	2,701,085
Capital increase		170,064	-	170,064	-	(170,000)	-	-	-	-	-	-	64	-	64
Hermes Pardini business combination		849,016	-	849,016	1,312,087	-	-	-	-	-	73,884	-	2,234,987	-	2,234,987
Expenditure with issue		-	(320)	(320)	-	-	-	-	-	-	-	-	(320)	-	(320)
Stock option plan		-	-	-	75	-	-	-	-	10,758	-	-	10,833	-	10,833
Non-controlling interest		-	-	-	-	-	-	-	-	-	-	-	-	(5,931)	(5,931)
Appropriation to investment reserve		-	-	-	-	162,453	-	-	(162,453)	-	-	-	-	-	-
Net income for the period		-	-	-	-	-	-	-	-	-	-	168,280	168,280	(414)	167,866
Balances at June 30, 2023		2,762,903	(26,921)	2,735,982	1,915,374	37,619	-	148,616	24,838	(9,213)	73,884	168,280	5,095,380	13,204	5,108,584
Balances at December 31, 2023		2,762,950	(26,921)	2,736,029	1,915,451	37,619	-	169,804	190,126	(39,462)	73,884	-	5,083,451	27,619	5,111,070
Formation of statutory reserve	23.b	-	-	-	-	-	84,752	-	(84,752)	-	-	-	-	-	-
Appropriation of additional dividends	23.c	-	-	-	-	-	-	-	(80,536)	-	-	-	(80,536)	-	(80,536)
Stock option plan	23.d	-	-	-	76	-	-	-	-	12,312	-	-	12,388	-	12,388
Non-controlling interest		-	-	-	-	-	-	-	-	-	-	-	-	47,646	47,646
Net income for the period		-	-	-	-	-	-	-	-	-	-	341,545	341,545	(1,068)	340,477
Balances at June 30, 2024		2,762,950	(26,921)	2,736,029	1,915,527	37,619	84,752	169,804	24,838	(27,150)	73,884	341,545	5,356,848	74,197	5,431,045

See the accompanying notes to the financial statements.

## Notes to the individual parent company and consolidated interim financial information as of June 30, 2024.

In thousands of reais (R\$), unless otherwise indicated.

	Note	Parent Company		Consolidated	
		06/30/2024	06/30/2023	06/30/2024	06/30/2023
<b>Net income for the period</b>		<b>341,545</b>	<b>168,280</b>	<b>340,477</b>	<b>167,866</b>
<b>Items not affecting cash:</b>					
Income tax and social contribution	20.b	37,071	23,613	104,591	55,360
Accrued financial income and expenses	30	183,247	231,517	211,605	257,431
Depreciation and amortization	27 26	231,054	237,434	381,358	297,338
Equity method and adjustment for realization at fair value	9	(118,137)	(73,602)	1,150	(255)
Long-term incentive		8,763	6,717	8,935	6,717
Formation (reversal) of provision for tax, labor and civil risks	21	(3,970)	694	636	562
Estimated losses from disallowances and default	25 29	50,891	23,450	64,514	29,596
Profit sharing		34,065	36,802	51,784	41,825
Other		39,189	2,465	32,971	5,316
<b>Cash flow from operating activities before changes in assets and liabilities</b>		<b>803,718</b>	<b>657,370</b>	<b>1,198,021</b>	<b>861,756</b>
(Increase) decrease in accounts receivable	5	(184,294)	(142,211)	(318,369)	(201,861)
(Increase) decrease in inventories	6	(3,442)	4,419	(4,622)	5,664
(Increase) decrease in recoverable taxes	7	2,134	(18,519)	(2,417)	(15,364)
(Increase) decrease in judicial deposits	21	63	(314)	(1,165)	910
(Increase) decrease in other assets	8	(1,488)	(16,928)	(9,041)	(15,085)
Increase (decrease) in suppliers	12	16,431	(6,220)	56,062	(11,642)
Increase (decrease) in labor obligations	16	(40,145)	(27,690)	(37,822)	(19,003)
Increase (decrease) in tax liabilities	17	5,204	8,183	8,759	1,405
Increase (decrease) in scheduling of tax payments	17	1,064	138	(5,236)	(4,928)
Increase (decrease) in other liabilities		3,933	44,503	(10,059)	237
<b>Total change in assets and liabilities</b>		<b>(200,540)</b>	<b>(154,639)</b>	<b>(323,910)</b>	<b>(259,667)</b>
Income tax and social contribution paid		(31,496)	(57,328)	(65,947)	(67,505)
<b>Net cash from operating activities</b>		<b>571,682</b>	<b>445,403</b>	<b>808,164</b>	<b>534,584</b>
Acquisition of fixed and intangible assets	10	(121,642)	(150,621)	(164,901)	(176,644)
Securities - funding and income	4	(1,007,529)	539,754	(1,080,841)	422,527
Payments for acquired companies less cash and cash equivalents	18	(2,769)	(50,212)	(112,244)	105,931
Acquisition of other ownership interests	9	-	-	-	(14,333)
Paid-up capital in subsidiary	9	(71,193)	(223,633)	-	-
Other		703	-	(13,478)	6,087
<b>Net cash generated (used) in investment activities</b>		<b>(1,202,430)</b>	<b>115,288</b>	<b>(1,371,464)</b>	<b>343,568</b>
Funding of debentures	14	1,000,000	-	1,000,000	-
(Principal) repayment of financing and debentures	14 13	-	(250,000)	(186)	(250,329)
Interest paid on financing and debentures	14 13	(171,452)	(177,720)	(171,544)	(177,745)
Financial commissions and other		(2,224)	(1,875)	(2,675)	(2,067)
Payment of lease	15	(126,257)	(127,714)	(199,809)	(154,048)
Capital increase	23a	-	-	-	(273,225)
Dividends and interest on own capital	23	(81,029)	-	(81,029)	-
Supplier financing - drawee risk		4,347	(6,474)	7,035	(6,482)
<b>Net cash (from) used in financing activities</b>		<b>623,385</b>	<b>(563,783)</b>	<b>551,792</b>	<b>(863,896)</b>
<b>Increase (decrease) in cash and cash equivalents</b>		<b>(7,363)</b>	<b>(3,092)</b>	<b>(11,508)</b>	<b>14,256</b>
<b>Cash and cash equivalents</b>					
At the beginning of the year	4	9,675	9,121	21,920	17,256
At the end of the year	4	2,312	6,029	10,412	31,512
<b>Changes in cash and cash equivalents</b>		<b>(7,363)</b>	<b>(3,092)</b>	<b>(11,508)</b>	<b>14,256</b>

See the accompanying notes to the financial statements.

	Parent Company		Consolidated	
	06/30/2024	06/30/2023	06/30/2024	06/30/2023
<b>Revenues</b>	<b>2,304,565</b>	<b>2,143,783</b>	<b>4,146,870</b>	<b>3,093,742</b>
Gross revenue from services rendered (net)	2,346,198	2,160,015	4,185,846	3,110,499
Estimated losses from disallowances	(47,407)	(20,665)	(57,878)	(25,164)
Other revenues	5,774	4,433	18,902	8,407
<b>Inputs acquired from third parties</b>	<b>(875,442)</b>	<b>(850,985)</b>	<b>(1,806,868)</b>	<b>(1,352,826)</b>
Cost of services rendered	(807,328)	(732,349)	(1,663,477)	(1,205,130)
Materials, energy, outsourced services and other	(65,696)	(117,719)	(143,429)	(148,183)
(Loss)/recovery of asset values	(2,418)	(917)	38	487
<b>Gross added value</b>	<b>1,429,123</b>	<b>1,292,798</b>	<b>2,340,002</b>	<b>1,740,915</b>
Depreciation and amortization	(231,054)	(237,434)	(381,358)	(297,338)
<b>Net added value</b>	<b>1,198,069</b>	<b>1,055,364</b>	<b>1,958,644</b>	<b>1,443,577</b>
<b>Added value received as transfer</b>	<b>167,568</b>	<b>141,470</b>	<b>77,885</b>	<b>108,129</b>
Equity method and adjustment for realization at fair value	118,137	73,602	(1,150)	255
Financial income (except PIS and COFINS)	49,431	67,868	79,035	107,874
<b>Total added value payable</b>	<b>1,365,637</b>	<b>1,196,834</b>	<b>2,036,529</b>	<b>1,551,707</b>
<b>Distribution of added value</b>	<b>(1,365,637)</b>	<b>(1,196,834)</b>	<b>(2,036,529)</b>	<b>(1,551,707)</b>
<b>Personnel and charges</b>	<b>(503,857)</b>	<b>(525,904)</b>	<b>(837,270)</b>	<b>(690,072)</b>
Direct remuneration	(364,500)	(367,974)	(615,932)	(492,263)
Benefits	(109,798)	(126,091)	(169,983)	(155,861)
Charges	(29,559)	(31,839)	(51,355)	(41,948)
<b>Taxes, rates and contributions</b>	<b>(274,408)</b>	<b>(252,131)</b>	<b>(522,711)</b>	<b>(371,423)</b>
Federal	(202,856)	(185,193)	(398,687)	(278,627)
Municipal	(71,552)	(66,938)	(121,922)	(92,581)
State	-	-	(2,102)	(215)
<b>Interest, rental and other operating expenses</b>	<b>(245,827)</b>	<b>(250,519)</b>	<b>(336,071)</b>	<b>(322,346)</b>
Rents	3,124	(361)	(8,953)	(6,638)
Interest	(230,412)	(233,198)	(287,284)	(292,935)
Other operating expenses	(18,539)	(16,960)	(39,834)	(22,773)
<b>Income for the period</b>	<b>(341,545)</b>	<b>(168,280)</b>	<b>(340,477)</b>	<b>(167,866)</b>

See the accompanying notes to the financial statements.

## 1. Operations

### 1.1 The Company

Fleury S.A. ("Fleury", "Parent Company" or "Company" and, together with its subsidiaries, "Fleury Group" or "Group") is a publicly-held corporation listed in the Novo Mercado segment of B3 S.A. – Brasil, Bolsa e Balcão, under the ticker "FLRY3", headquartered in the city of São Paulo. The Company is engaged in the provision of medical services in the diagnostic, laboratory support (Lab-to-Lab), infusions, clinical analysis, health management, medical care, orthopedics and ophthalmology areas, toxicological exam served by a digital healthcare platform. The Group is present in 11 Brazilian States, including the major capital cities in Brazil (São Paulo, Rio de Janeiro, Brasília and Belo Horizonte), with 555 service units and mobile service operations engaging approximately 23 employees and 4 doctors.

### 1.2 New businesses – Gênesis

In April 2024, Gênesis operations started, a Joint Venture with Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, to perform genomic tests, as well as in the development of integrated solutions, research, development of processes and services to directly serve the personalized and precision medicine market in general. Fleury has majority ownership and control of Gênesis, with its numbers consolidated as of this date. The contributions made by Gênesis were essentially in Cash, Property and Equipment, and Inventory.

### 1.3 Business combination – São Lucas

On April 22, 2024, the Company entered into a Share Purchase Agreement for the acquisition of all the shares issued by the companies that make up São Lucas Centro de Diagnóstico: (i) Eco Rad Serviços Médicos Ltda.; (ii) Clínica São Lucas de Balneário Camboriú Ltda.; (iii) Serviços Laboratoriais Liberado Ltda.; (iv) Serviços Médicos Clínica São Lucas Ltda. and (v) São Lucas Centro de Diagnóstico por Imagem Ltda. The "São Lucas" laboratory provides diagnostic imaging and clinical analysis services through five units in Itajaí and Balneário Camboriú in Santa Catarina. The value of the Acquisition is R\$ 69.8 million (Enterprise Value), and is subject to certain adjustments and withholdings, as provided for in the CCVA. The completion of the Acquisition is contingent on the fulfillment of certain conditions precedent. There were no effects recorded in these financial statements.

### 1.4 9<sup>th</sup> Issue of Debentures

On May 10, 2024, the Company placed a ninth issue of unsecured, sole series debentures non-convertible into shares, in two series ("Debentures"), in the total amount of R\$ 1,000,000,000.00 (one billion reais). The funds raised will be appropriated to general corporate use, such as strengthening working capital and/or extending the Company's liabilities.

## 1.5 Floods of the State of Rio Grande do Sul

In early May, the state of Rio Grande do Sul was hit by heavy rains that caused flooding in several cities. The Company has 23 care units and 3 hospitals in the region, but without material impacts that need to be reported in this statement.

## 2. Presentation of the financial statements

The Audit Committee recommended the approval of the financial statements to the Board of Directors on August 06, 2024 which were approved by the Board of Directors on August 07, 2024.

The individual parent company and consolidated financial quarterly information was prepared and is being presented according to the accounting practices adopted in Brazil, including the pronouncements issued by the Accounting Pronouncement Committee (CPC), as well as by the International Financial Reporting Standards (IFRS - IAS 34) issued by the International Accounting Standards Board (IASB).

The accounting practices and policies (which include the principles of measurement, recognition and valuation of assets and liabilities), in addition to the main accounting judgments and sources of uncertainty about estimates adopted in the preparation of this quarterly information, are consistent with those adopted and disclosed in annual financial statements for the year ended December 31, 2023 and, therefore, must be analyzed as a whole.

All relevant information of significance used by Management in performing its duties is presented in these financial statements, as per OCPC07.

The individual parent company and consolidated quarterly information is presented in thousands of Reais, which is the functional currency of Fleury Group.

### a) Subsidiaries and jointly-controlled subsidiary

The consolidated financial statements include the balances of Fleury S.A., its subsidiaries and special-purpose entities represented by exclusive investment funds. In addition, the balance includes an equity interest in a jointly-controlled company, accounted for under the equity method as follows:

	<b>Ownership percentage of Fleury S.A.</b>	
	<b>06/30/2024</b>	<b>12/31/2023</b>
<b>Direct subsidiaries:</b>		
Centro de Infusões Pacaembu Ltda. ("CIP")	100%	100%
Fleury Centro de Procedimentos Médicos Avançados S.A. ("Fleury CPMA")	100%	100%
Fundo de Investimento Kortex Ventures ("Kortex")	54%	54%
Gênesis Análises Genômicas S.A. <b>(a)</b>	55%	-
Instituto Hermes Pardini S.A. ("Hermes Pardini")	100%	100%
Métodos Laboratório, Análises Clínicas e Hematologia Ltda.	100%	100%
<b>Indirect subsidiaries:</b>		
Centro Avançado de Oftalmologia S.A. (Moacir Group)	80%	80%
Clínica de Olhos Dr. Moacir Cunha S.A. (Moacir Group)	80%	80%
CPC – Centro de Patologia Clínica Ltda.	100%	100%

CSV - Central Sorológica de Vitória Ltda. <b>(b)</b>	-	99%
Diagnóstico por Imagem Sete Lagoas Ltda. (CEMED)	100%	100%
Fleury Serviços Ortopédicos S.A. (Holding company Vita)	67%	67%
HSB - Hugo Silviano Brandão Ltda.	100%	100%
Instituto 9 de julho - Serviços Médicos S.A. (Moacir Group)	80%	80%
IACS - Instituto de Análises Clínicas de Santos S.A. <b>(c)</b>	95.2%	60%
IRN - Instituto de Radiologia de Natal Ltda.	100%	100%
Laboratório Bioclínico Ltda.	100%	100%
Laboratório de Pat. Clínica Dr. Paulo Cordeiro de Azevedo Ltda. (LPA)	100%	100%
Laboratório Padrão S.A.	100%	100%
Laboratório Pretti Ltda.	100%	100%
Moscogliato - Serviço de Ultrassom Ltda. (Clínica Dra. Odivânia)	100%	100%
PARDIS - Pardini Distribuidora Ltda.	100%	100%
Clínica Oftalmológica São Lucas Ltda. (Retina Clinic)	100%	100%
Saha Centro de Infusões Ltda.	100%	100%
Saha Serviços Médicos e Hospitalares Ltda.	100%	100%
Sansão Holding S.A.	100%	100%
SantéCorp Ltda.	100%	100%
Saúde iD Ltda.	100%	100%
Toxicologia Pardini Laboratórios S.A.	100%	100%
Vita Clínicas Medicina Especializada Ltda.	100%	100%

#### Exclusive Investment Funds:

Bradesco Fundo de Investimento em cotas FI Renda Fixa Crédito Privado Exclusivo Beta	100%	100%
Santander FI Exclusivo Alpha Renda Fixa Crédito Longo Prazo	-	100%
Itaú Fundo de Investimento Ômega CIC RF referenciado DI - Resp. Limitada	100%	-

#### Jointly-controlled subsidiary:

ABPF Oncologia S.A.	33.33%	33.33%
---------------------	--------	--------

(a) Operation with Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, with its activities starting as of April 2024.

(b) Merged on March 01, 2024 by Instituto Hermes Pardini S.A.

(c) Exercise of the purchase option of IACS by Instituto Hermes Pardini S.A.

#### Main activities:

**Fleury S.A.:** diagnostic imaging, clinical analysis, fertility, infusions, genomics;

**Fleury CPMA:** diagnostic imaging in certain hospitals, clinical analysis and day clinic;

**Grupo IRN:** diagnostic imaging services;

**SantéCorp:** health management including telemedicine;

**CPC, Pretti, Bioclínico and Méthodos:** clinical analysis laboratory services;

**Saúde iD:** health platform;

**CIP and Saha:** hospital and immunobiological drug infusion center;

**Clínica de Olhos Dr. Moacir Cunha:** ophthalmology service centers;

**Vita:** medicine services specialized in orthopedics;

**Instituto Hermes Pardini:** clinical analysis, medical imaging, laboratory support (Lab-to-Lab);

**Pardis:** resale of merchandise for application in the processing of clinical analysis;

**Toxicologia Pardini:** toxicological exam;

**ABPF Oncologia:** preventive, integrated solutions, and clinical research in oncology;

**Kortex:** investment fund in startups engaged in digital health, diagnostic medicine and personalized medicine.

**Genesis:** integrated solutions, research, development of processes and services in genomics.

## **b) Accounting standards and interpretations in force and not yet in force**

New accounting standards and interpretations have not materially impacted these financial statements.

### **i) IFRS S1 and S2 standards – General Requirements for Disclosure of Sustainability-related Financial Information and Climate-related Disclosures**

In compliance with CVM Resolution 193/2023, which requires an entity to disclose information on its sustainability-related risks and opportunities, as well as requirements to identify, measure and disclose information on climate-related risks and opportunities, the Company is assessing the impacts of the standard for the compliance with the deadline defined therein on or after January 01, 2026.

### **ii) IFRS 18 Standard – Presentation and Disclosure of Financial Statements**

IFRS 18 introduces sets of new requirements to foster consistency in the presentation and disclosure of financial statements. The main changes to the standard are as follows: i) New categories and subtotals in the statement of income: operational, investment, and financing; ii) Disclosure of non-GAAP metrics (EBITDA) in notes; and iii) Presentation of operating expenses specified by type. The company is assessing the impacts of the standard to comply with the effective date of January 1, 2027.

## **3. Risk management**

The main risk factors to which the Company and its subsidiaries are exposed are financial, operational and environmental risks, including market, foreign exchange, interest rate, credit and liquidity risk. These risks, which are inherent to their activities, are managed through internal policies and controls supervised and monitored through monthly management reports.

### **Fair value hierarchy**

The assumptions used by the Company to determine the hierarchy and disclose the fair values of financial instruments are as follows:

- Level 1: quoted price in active markets for identical assets or liabilities;
- Level 2: techniques that determine fair value based on observable factors, either directly or indirectly.
- Level 3: techniques based on internal methodologies that are not based on observable data in the market.



## a) Accounting classification and fair values

Financial assets	Level 1	Level 2
Cash and cash equivalents	10,412	-
Securities	-	2,116,536
Accounts receivable	1,761,814	-
Other call option credits	18,179	-
<b>Financial liabilities</b>		
Suppliers	(676,475)	-
Lease	(1,342,602)	-
Financing, except supplier financing - drawee risk	(2,827)	-
Supplier financing - drawee risk	(18,725)	-
Debentures	-	(3,791,356)
Tax installments	(16,252)	-
Interest on own capital (JCP) and dividends paid	(263)	-
Accounts payable - Acquisition of companies	(319,479)	(8,585)
<b>Balances at June 30, 2024</b>	<b>(586,218)</b>	<b>(1,683,405)</b>
<b>December 31, 2023</b>	<b>(864,688)</b>	<b>(1,828,309)</b>

Due to the nature of balances, the fair value of the Company's financial instrument balances approximate their book values. The comparison did not present material differences.

## b) Capital management

Fleury Group monitors capital based on the consolidated leverage ratio, as shown below:

	06/30/2024	12/31/2023
Financing and debentures, except supplier financing - drawee risk	3,794,183	2,797,883
Accounts payable – Acquisition of companies	328,064	397,673
Supplier financing - drawee risk	18,725	11,690
Cash and cash equivalents	(10,412)	(21,920)
Securities	(2,116,536)	(1,035,695)
<b>Net debt</b>	<b>2,014,024</b>	<b>2,149,631</b>
EBITDA LTM* (Earnings before interest, taxes, depreciation and amortization)	1,920,978	1,745,669
<b>Leverage ratio (Net debt / EBITDA LTM*)</b>	<b>1.05</b>	<b>1.23</b>

(\*) LTM (last twelve months)

## c) Financial and market risks

### Liquidity risk

The chart below analyzes Fleury Group's liabilities and financial instruments, by maturity brackets, corresponding to the remaining period in the balance sheet up to the contractual date of maturity. The amounts disclosed are contracted (consolidated) undiscounted cash flows, and, therefore, they do not agree directly with the book values.

June 30, 2024	Book value	Amount contracted	≤01 year	01–02 years	02–05 years	>05 years
Debentures	3,791,356	5,297,755	610,013	729,147	3,377,693	580,902
Lease	1,342,602	1,916,635	395,211	357,980	611,846	551,598
Suppliers	676,475	676,475	676,475	-	-	-
Accounts payable - acquisition of companies	328,064	478,289	44,017	88,432	139,748	206,092
Other liabilities	26,325	26,325	26,325	-	-	-
Supplier financing - drawee risk	18,725	18,725	18,725	-	-	-
Financing	2,827	3,364	961	929	1,474	-
	<b>6,186,374</b>	<b>8,417,568</b>	<b>1,771,727</b>	<b>1,176,488</b>	<b>4,130,761</b>	<b>1,338,592</b>

### Foreign exchange risk

The Fleury Group uses derivatives to hedge exposures to foreign currency of certain suppliers of inputs. Derivatives are recognized at fair value on their execution date and remeasured on a monthly basis. The effects on income (loss) are recognized in Financial income and/or expenses.

The equity balance of these liabilities as at June 30, 2024 is R\$ 6,878, and the net derivative of this operation is R\$ 367.

The other information did not undergo significant changes in relation to that disclosed on December 31, 2023, Note 4 - Risk Management.

### d) Operational and Environmental Risk Management

The operational and environmental risk management governance policies are consistent with those adopted and disclosed in the annual financial statements of Fleury S.A. for the year ended December 31, 2023.

### e) Statement of sensitivity analysis

#### Sensitivity analysis for interest rate changes

To calculate the probable scenario, the projections disclosed by the Market Focus Report published by the Central Bank of Brazil on June 30, 2024 were used. The "Possible" and "Remote" scenarios consider an increase in this rate of 0.50% p.a.

The results in nominal terms were as follows:

	Book balance	Probable	Possible	Remote
	<b>CDI (p.a.)</b>	<b>10.40%</b>	<b>10.90%</b>	<b>11.40%</b>
Interest earning bank deposits - securities	2,116,536	220,120	230,702	241,285
Debentures	(3,791,356)	(394,301)	(413,258)	(432,214)
<b>Net exposure in CDI</b>	<b>(1,674,820)</b>	<b>(174,181)</b>	<b>(182,556)</b>	<b>(190,929)</b>

#### 4. Securities

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
Fund quotas - Pegged to the DI rate (a)	1,639,283	640,566	2,094,910	1,016,095
BANK DEPOSIT CERTIFICATES (CDB)	20,495	19,408	20,495	19,407
Kortex Venture Capital - Fixed income funds	22,636	14,911	1,131	193
<b>Total</b>	<b>1,682,414</b>	<b>674,885</b>	<b>2,116,536</b>	<b>1,035,695</b>
<b>Current</b>	<b>1,639,284</b>	<b>640,566</b>	<b>1,993,649</b>	<b>902,213</b>
<b>Non-current</b>	<b>43,130</b>	<b>34,319</b>	<b>122,887</b>	<b>133,482</b>

(a) Remunerated at the weighted average rate of 106.99% of CDI in June 2024 (105.76% in December 2023).

#### (a) Changes in the financial investments balance (securities + investments with daily liquidity)

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
Opening balance	674,885	1,207,438	1,035,695	1,413,875
Investment	2,408,997	2,455,328	3,376,722	4,166,126
Business combination	-	-	-	15,064
Earnings	42,880	108,900	65,726	151,273
Redemption	(1,444,348)	(3,096,781)	(2,361,607)	(4,710,643)
<b>Total</b>	<b>1,682,414</b>	<b>674,885</b>	<b>2,116,536</b>	<b>1,035,695</b>

#### 5. Accounts receivable

##### a) Breakdown of balance

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
Amounts billed	762,404	662,379	1,244,706	1,076,437
Amounts to be billed	241,688	179,788	592,410	474,497
	<b>1,004,092</b>	<b>842,167</b>	<b>1,837,116</b>	<b>1,550,934</b>
Estimated losses from disallowances and default	(49,694)	(21,172)	(75,302)	(43,192)
<b>Total</b>	<b>954,398</b>	<b>820,995</b>	<b>1,761,814</b>	<b>1,507,742</b>
<b>Current</b>	<b>954,398</b>	<b>820,995</b>	<b>1,759,050</b>	<b>1,505,194</b>
<b>Non-current</b>	<b>-</b>	<b>-</b>	<b>2,764</b>	<b>2,548</b>

The Company and its subsidiaries have a certain degree of concentration in their client portfolios (legal entity). As of June 30, 2024, the six main clients accounted for 52.45% of the total portfolio (48.89% as of December 31, 2023).

## b) Aging analysis

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
<b>Not yet due</b>	778,982	695,288	1,488,442	1,300,368
<b>Overdue</b>				
≤120	136,537	96,676	213,110	170,357
121–360	79,696	47,507	119,726	71,688
>361	8,877	2,696	15,838	8,521
<b>Total</b>	<b>1,004,092</b>	<b>842,167</b>	<b>1,837,116</b>	<b>1,550,934</b>

## c) Changes in estimated losses from disallowances and default

	Parent Company		Consolidated	
	06/30/2024	06/30/2023	06/30/2024	06/30/2023
<b>Balance at the beginning of the period</b>	(21,172)	(12,915)	(43,192)	(14,566)
Additions of disallowances and default (Notes 25 and 29)	(47,407)	(21,634)	(57,878)	(26,186)
Business combination	-	-	-	(17,887)
Write-off of non-collectible securities	18,885	18,976	25,768	21,287
<b>Balance at the end of the period</b>	<b>(49,694)</b>	<b>(15,573)</b>	<b>(75,302)</b>	<b>(37,352)</b>

## 6. Inventories

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
Diagnostic kits	31,046	27,881	70,957	59,645
Auxiliary laboratory materials (Infusion)	1,221	1,537	22,869	23,451
Auxiliary laboratory materials	11,262	9,881	18,150	22,151
Nursing and sample collection materials	13,095	13,747	15,623	16,810
Administrative, promotional and other materials	3,536	3,672	7,308	8,669
Good for resale	-	-	3,037	2,499
Auxiliary laboratory materials (Ophthalmology)	-	-	1,607	1,704
<b>Total</b>	<b>60,160</b>	<b>56,718</b>	<b>139,551</b>	<b>134,929</b>

## 7. Recoverable taxes

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
ISS	7,095	7,748	8,509	8,737
PIS AND COFINS	378	378	3,846	2,107
ICMS	-	-	1,823	2,562
INSS	839	1,421	1,107	6,874
<b>Total</b>	<b>8,312</b>	<b>9,547</b>	<b>15,285</b>	<b>20,280</b>

## 8. Other assets

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
Advance to suppliers	7,690	10,069	28,583	30,024
Costs with obtaining contracts (a)	20,980	17,853	20,980	17,853
Employee credits/payroll	14,570	17,789	20,840	21,318
Prepaid expenses (b)	11,281	5,679	18,877	11,336
Financial asset - Call option Vita (c)	-	-	18,179	18,179
Reimbursement of former sellers/related parties (d)	-	-	12,841	-
Rental advances	1,072	3,215	1,072	3,215
Other credits receivable	1,873	1,027	4,227	2,167
<b>Total</b>	<b>57,466</b>	<b>55,632</b>	<b>125,599</b>	<b>104,092</b>
<b>Current</b>	<b>29,966</b>	<b>26,299</b>	<b>79,884</b>	<b>56,535</b>
<b>Non-current</b>	<b>27,500</b>	<b>29,333</b>	<b>45,715</b>	<b>47,557</b>

(a) Refers to a partnership agreement with hospitals to obtain a contract to provide clinical analysis services. The amounts are amortized over the contractual term.

(b) Basically expenses for renewal of licenses, insurance, IPTU tax, guarantees and helium gas.

(c) Pursuant to the purchase and sale agreement entered into by Fleury CPMA and sellers, CPMA has the option (right) to acquire the non-controlling interest that represents 33.33%.

(d) It mainly consists of tax installment payment of companies acquired, which will be reimbursed by the former sellers.

## 9. Investments

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
Direct/indirect subsidiary	4,371,747	4,173,900	21,676	21,834
Investees of the Kortex Fund	-	-	41,787	27,882
ABPF Oncologia (JV)	13,341	14,491	13,341	14,491
Prontmed	12,000	12,000	12,000	12,000
Other interests	4,549	5,312	4,605	5,312
<b>Total</b>	<b>4,401,637</b>	<b>4,205,703</b>	<b>93,409</b>	<b>81,519</b>

### Significant information about Parent Company's investments

Direct subsidiaries	Base Date	Interest in paid-up capital - %	Capital quotas (qty)	Shareholders' equity	Income (loss) for the period
Fleury CPMA	06/30/2024	100%	1,021,594	973,721	18,662
	12/31/2023	100%	1,021,594	955,060	(9,418)
Hermes Pardini Group	06/30/2024	100%	1,196,065	1,518,019	114,313
	12/31/2023	100%	1,166,065	1,400,143	116,968
CIP Group	06/30/2024	100%	87,131	165,824	14,597
	12/31/2023	100%	79,611	143,707	37,211
Métodos	06/30/2024	100%	2,336	10,439	4,147
	12/31/2023	100%	2,336	6,854	5,266
Genesis	06/30/2024	55%	60,817	56,077	(2,688)
	12/31/2023	-	-	-	-

## Changes in balances of investments:

### Parent Company – Fleury S.A., investor:

Investees	Balance at 12/31/2023	Full. Capital	Equity in results of subsidiaries	Realization of surplus and loss	Realization of lawsuits (possible losses)	Other changes	Balance at 06/30/2024
IHP Group	2,916,585	30,000	114,314	(29,499)	7,367	-	3,038,767
Fleury CPMA	955,075	-	18,662	-	-	-	973,737
CIP Group	269,413	7,520	14,597	(40)	-	-	291,490
Métodos	32,827	-	4,147	(206)	-	-	36,768
Genesis	-	33,673	(2,688)	-	-	-	30,985
ABPF Oncologia	14,491	-	(1,150)	-	-	-	13,341
Prontmed	12,000	-	-	-	-	-	12,000
Other	5,312	-	-	-	-	(763)	4,549
<b>Total</b>	<b>4,205,703</b>	<b>71,193</b>	<b>147,882</b>	<b>(29,745)</b>	<b>7,367</b>	<b>(763)</b>	<b>4,401,637</b>

### Changes - Consolidated:

Investor	Investees	Balance at 12/31/2023	Paid-up capital	Equity in results of subsidiaries	Surplus (Note 10)	Other changes	Balance at 06/30/2024
Kortex	Sundry	27,882	13,506	-	-	399	41,787
Fleury/CPMA	Acquired	21,834	-	-	(12,492)	12,334	21,676
Fleury S.A.	ABPF Oncologia	14,491	-	(1,150)	-	-	13,341
Fleury S.A.	Prontmed	12,000	-	-	-	-	12,000
Fleury S.A.	Other	5,312	-	-	-	(707)	4,605
<b>Total consolidated</b>		<b>81,519</b>	<b>13,506</b>	<b>(1,150)</b>	<b>(12,492)</b>	<b>12,026</b>	<b>93,409</b>

## 10. Property, plant and equipment and intangible assets

### a) Breakdown of balance of property, plant and equipment

Parent Company	Average annual depreciation rate (%)	Cost	Accumulated depreciation	Net balance at 06/30/2024	Net balance at 12/31/2023
Machinery and equipment	10	908,393	(513,467)	394,926	401,322
Leasehold improvements	20	647,410	(424,694)	222,716	221,511
Facilities	10	349,239	(282,673)	66,566	64,888
Construction in progress	-	45,935	-	45,935	70,469
IT equipment	20	123,090	(100,514)	22,576	24,830
Properties	2	27,760	(8,005)	19,755	19,988
Furniture and fixtures	10	56,277	(42,256)	14,021	13,979
Land	-	13,637	-	13,637	13,637
Vehicles	20	731	(642)	89	90
<b>Total</b>		<b>2,172,472</b>	<b>(1,372,251)</b>	<b>800,221</b>	<b>830,714</b>

Consolidated	Average annual depreciation rate (%)	Cost	Accumulated depreciation	Net balance at 06/30/2024	Net balance at 12/31/2023
Machinery and equipment	10	1,596,037	(896,943)	699,094	707,548
Leasehold improvements	20	915,563	(535,304)	380,259	377,489
Facilities	10	403,518	(326,593)	76,925	71,956
Construction in progress	-	50,680	-	50,680	73,035
IT equipment	20	198,717	(156,049)	42,668	45,784
Furniture and fixtures	10	110,764	(74,088)	36,676	38,380
Properties	2	27,762	(8,006)	19,756	19,987
Land	-	13,637	-	13,637	13,637
Vehicles	20	3,827	(3,330)	497	676
<b>Total</b>		<b>3,320,505</b>	<b>(2,000,313)</b>	<b>1,320,192</b>	<b>1,348,492</b>

## b) Changes in property, plant and equipment balances

Parent Company	Balance at 12/31/2023	Additions	Net write-offs (a)	Depreciation	Reclass. /Transfer	Balance at 06/30/2024
Machinery and equipment	401,322	5,637	(18,324)	(30,384)	36,675	394,926
Leasehold improvements	221,511	26,597	(532)	(32,616)	7,756	222,716
Facilities	64,888	4,473	(2,134)	(5,611)	4,950	66,566
Construction in progress	70,469	25,765	(309)	-	(49,990)	45,935
IT equipment	24,831	1,486	(97)	(4,383)	739	22,576
Properties	19,987	-	-	(232)	-	19,755
Furniture and fixtures	13,979	617	(51)	(1,204)	680	14,021
Land	13,637	-	-	-	-	13,637
Vehicles	90	-	-	(1)	-	89
<b>Total</b>	<b>830,714</b>	<b>64,575</b>	<b>(21,447)</b>	<b>(74,431)</b>	<b>810</b>	<b>800,221</b>

(a) They mainly refer to the contribution made in Genesis (R\$ 15,646), as mentioned in Operations, 1.2 New Business – Genesis.

Parent Company	Balance at 12/31/2022	Additions	Net write-offs	Depreciation	Merger	Reclass. /Transfer	Balance at 06/30/2023
Machinery and equipment	382,551	15,951	(1,478)	(30,518)	847	37,255	404,608
Leasehold improvements	144,712	5,189	(80)	(34,612)	1,129	108,336	224,674
Facilities	53,257	5,978	(479)	(10,809)	446	17,495	65,888
Construction in progress	176,380	27,421	(240)	-	-	(167,074)	36,487
IT equipment	30,258	3,650	-	(5,152)	436	345	29,537
Properties	20,645	-	-	(233)	-	-	20,412
Furniture and fixtures	11,877	63	(140)	(1,167)	102	4,098	14,833
Land	13,637	-	-	-	-	-	13,637
Vehicles	62	-	-	32	-	-	94
<b>Total</b>	<b>833,379</b>	<b>58,252</b>	<b>(2,417)</b>	<b>(82,459)</b>	<b>2,960</b>	<b>455</b>	<b>810,170</b>



Consolidated	Balance at 12/31/2023	Additions	Net write-offs	Depreciation	Reclass. /Transf.	Genesis Operation (a)	Balance at 06/30/2024
Machinery and equipment	707,548	19,855	(3,572)	(69,192)	37,353	7,102	699,094
Leasehold improvements	377,489	36,265	(584)	(41,155)	8,244	-	380,259
Facilities	71,956	6,363	(750)	(6,067)	5,423	-	76,925
IT equipment	45,784	2,636	(31)	(7,436)	1,550	165	42,668
Construction in progress	73,035	26,469	(61)	-	(51,566)	2,803	50,680
Furniture and fixtures	38,380	1,331	(66)	(3,648)	679	-	36,676
Properties	19,987	-	-	(231)	-	-	19,756
Land	13,637	-	-	-	-	-	13,637
Vehicles	676	-	(35)	(144)	-	-	497
<b>Total</b>	<b>1,348,492</b>	<b>92,919</b>	<b>(5,099)</b>	<b>(127,873)</b>	<b>1,683</b>	<b>10,070</b>	<b>1,320,192</b>

(a) They refer to net assets on the initial date of consolidation, as mentioned in the Operations, 1.2 New Businesses - Genesis.

Consolidated	Balance at 12/31/2022	Business combination	Additions	Net write-offs	Depreciation	Surplus and loss	Reclass./ Transfer	Balance at 06/30/2023
Machinery and equipment	428,723	187,048	22,799	(1,693)	(43,412)	102,783	37,878	734,126
Leasehold improvements	170,578	130,454	9,643	(90)	(39,650)	(370)	109,076	379,641
Facilities	58,838	2,504	6,003	(564)	(11,173)	1,470	17,406	74,484
IT equipment	35,355	8,401	4,026	(413)	(6,634)	6,644	344	47,723
Construction in progress	177,790	447	28,155	(249)	-	-	(168,873)	37,270
Furniture and fixtures	19,472	14,394	801	(365)	(2,150)	6,836	4,133	43,121
Properties	20,645	-	-	-	(234)	-	1	20,412
Land	13,637	-	-	-	-	-	-	13,637
Vehicles	845	386	-	-	(301)	(10)	-	920
<b>Total</b>	<b>925,883</b>	<b>343,634</b>	<b>71,427</b>	<b>(3,374)</b>	<b>(103,554)</b>	<b>117,353</b>	<b>(35)</b>	<b>1,351,334</b>

### c) Balances

Parent Company	Average annual amortization rate (%)	Cost	Accumulated amortization	Net balance at 06/30/2024	Net balance at 12/31/2023
Goodwill	-	1,817,692	(44,413)	1,773,279	1,773,279
Licenses and software	20	811,489	(645,583)	165,906	168,127
Construction in progress	-	122,894	-	122,894	139,790
Trademarks and patents	7	91,018	(10,884)	80,134	80,300
Products developed	3	3,109	-	3,109	6,690
<b>Total</b>		<b>2,846,202</b>	<b>(700,880)</b>	<b>2,145,322</b>	<b>2,168,186</b>

Consolidated	Average annual amortization rate (%)	Cost	Accumulated amortization	Net balance at 06/30/2024	Net balance at 12/31/2023
Goodwill	-	4,269,902	(45,213)	4,224,689	4,223,505
Trademarks and patents	7	756,308	(22,843)	733,465	722,819
Client contracts	10	553,117	(217,894)	335,223	352,391
Licenses and software	20	1,062,369	(765,236)	297,133	303,321
Construction in progress	-	144,498	-	144,498	160,211
Commercial points (Pardini)	10	42,742	(9,261)	33,481	35,619
Products developed	3	16,820	(2,029)	14,791	9,634
Non-competition agreement	7	868	(865)	3	6
<b>Total</b>		<b>6,846,624</b>	<b>(1,063,341)</b>	<b>5,783,283</b>	<b>5,807,506</b>

#### d) Changes in intangible asset balances

Parent Company	Balance at 12/31/2023	Additions	Write-offs (a)	Amortization	Transfers	Balance at 06/30/2024
Goodwill	1,773,279	-	-	-	-	1,773,279
Licenses and software	168,127	49,000	(2,310)	(70,846)	21,935	165,906
Construction in progress	139,790	6,076	(67)	(1)	(22,904)	122,894
Trademarks and patents	80,300	-	(4)	(162)	-	80,134
Products developed	6,690	1,991	(5,731)	-	159	3,109
<b>Total</b>	<b>2,168,186</b>	<b>57,067</b>	<b>(8,112)</b>	<b>(71,009)</b>	<b>(810)</b>	<b>2,145,322</b>

(a) They mainly refer to the contribution made in Genesis (R\$ 8,100), as mentioned in Operations, 1.2 New Business – Genesis.

Parent Company	Balance at 12/31/2022	Additions	Write-offs	Amortization	Merger	Transfers	Balance at 06/30/2023
Goodwill - Future profitability	1,467,728	-	-	-	304,200	-	1,771,928
Licenses and software	181,891	41,369	(36)	(60,650)	-	16,598	179,172
Construction in progress	89,255	51,072	-	-	349	(17,053)	123,623
Trademarks and patents	3,390	-	-	(168)	77,246	-	80,468
Internally developed products	6,690	-	-	-	-	-	6,690
<b>Total</b>	<b>1,748,954</b>	<b>92,441</b>	<b>(36)</b>	<b>(60,818)</b>	<b>381,795</b>	<b>(455)</b>	<b>2,161,881</b>

Consolidated	Balance at 12/31/2023	Additions	Write-offs	Amortization	Reclass. /Trans.	Surplus (Note 09)	Genesis Operation (a)	Balance at 06/30/2024
Goodwill - Future profitability	4,223,505	-	-	-	-	1,184	-	4,224,689
Trademarks and patents	722,819	-	-	(1,847)	-	12,493	-	733,465
Client contracts	352,391	-	-	(17,168)	-	-	-	335,223
Licenses and software	303,321	56,005	(1,255)	(90,849)	27,299	-	2,612	297,133
Construction in progress	160,211	13,831	-	-	(34,617)	-	5,073	144,498
Commercial points	35,619	-	-	(2,138)	-	-	-	33,481
Internally developed products	9,634	2,146	(1,991)	(633)	5,635	-	-	14,791
Non-competition agreement	6	-	-	(3)	-	-	-	3
<b>Total</b>	<b>5,807,506</b>	<b>71,982</b>	<b>(3,246)</b>	<b>(112,638)</b>	<b>(1,683)</b>	<b>13,677</b>	<b>7,685</b>	<b>5,783,283</b>

(a) They refer to net assets on the initial date of consolidation, as mentioned in the Operations, 1.2 New Businesses - Genesis.

Consolidated	Balance at 12/31/2022	Fair value in the acquisition of subsidiaries	Business combination	Additions	Write-offs	Amortization	Reclass. /Trans.	Surplus/loss	Balance at 06/30/2023
Goodwill - Future profitability	2,566,748	892,972	708,024	-	-	-	-	-	4,167,744
Trademarks and patents	247,544	426,984	69,770	-	-	(727)	-	(14,234)	729,337
Client contracts	735	350,319	14,244	-	-	(5,929)	-	(93)	359,276
Licenses and software	241,922	-	75,879	46,086	(36)	(72,269)	28,820	-	320,402
Construction in progress	96,087	-	18,829	58,712	(10)	-	(28,785)	-	144,833
Commercial points	-	-	38,470	-	-	(714)	-	-	37,756
Internally developed products	6,690	-	2,046	8	-	(121)	-	-	8,623
Non-competition agreement	200	-	-	-	-	-	-	(50)	150
<b>Total</b>	<b>3,159,926</b>	<b>1,670,275</b>	<b>927,262</b>	<b>104,806</b>	<b>(46)</b>	<b>(79,760)</b>	<b>35</b>	<b>(14,377)</b>	<b>5,768,121</b>

## 11. Right-of-use

### a) Balances

Parent Company	Average annual depreciation rate (%)	Cost	Accumulated amortization	Net balance at 06/30/2024	Net balance at 12/31/2023
Properties	13	1,270,882	(582,963)	687,919	739,420
Machinery and equipment	20	178,790	(98,837)	79,953	95,559
IT equipment	25	42,005	(29,413)	12,592	12,534
Vehicles	50	19,254	(16,180)	3,074	5,041
<b>Total</b>		<b>1,510,931</b>	<b>(727,393)</b>	<b>783,538</b>	<b>852,554</b>

Consolidated	Average annual depreciation rate (%)	Cost	Accumulated amortization	Net balance at 06/30/2024	Net balance at 12/31/2023
Properties	13	1,798,412	(793,415)	1,004,997	1,068,354
Machinery and equipment	20	334,849	(178,755)	156,094	180,711
IT equipment	25	63,272	(36,629)	26,643	26,072
Vehicles	50	45,356	(30,981)	14,375	19,958
<b>Total</b>		<b>2,241,889</b>	<b>(1,039,780)</b>	<b>1,202,109</b>	<b>1,295,095</b>

## b) Changes

Parent Company	Balance at 12/31/2023	Additions	Renegotiations	Write-offs	Amortizations	Balance at 06/30/2024
Properties	739,420	11,670	2,566	(717)	(65,020)	687,919
Machinery and equipment	95,559	-	-	-	(15,606)	79,953
IT equipment	12,534	3,089	-	(10)	(3,021)	12,592
Vehicles	5,041	-	-	-	(1,967)	3,074
<b>Total</b>	<b>852,554</b>	<b>14,759</b>	<b>2,566</b>	<b>(727)</b>	<b>(85,614)</b>	<b>783,538</b>

Parent Company	Balance at 12/31/2022	Additions	Renegotiations	Amortizations	Write-offs	Merger	Balance at 06/30/2023
Properties	808,832	30,960	12,929	(61,094)	(25,129)	22,008	788,506
Machinery and equipment	83,800	43,777	1,129	(16,873)	-	-	111,833
IT equipment	19,048	2,070	-	(4,809)	(857)	-	15,452
Vehicles	7,823	1,321	314	(2,349)	(30)	-	7,079
<b>Total</b>	<b>919,503</b>	<b>78,128</b>	<b>14,372</b>	<b>(85,125)</b>	<b>(26,016)</b>	<b>22,008</b>	<b>922,870</b>

Consolidated	Balance at 12/31/2023	Additions	Renegotiations	Decrease	Amortizations	Other changes	Balance at 06/30/2024
Properties	1,068,354	38,093	4,320	(5,315)	(100,390)	(65)	1,004,997
Machinery and equipment	180,711	6,865	107	(1,038)	(30,551)	-	156,094
IT equipment	26,072	5,156	461	(17)	(5,029)	-	26,643
Vehicles	19,958	2,669	(18)	(3,357)	(4,877)	-	14,375
<b>Total</b>	<b>1,295,095</b>	<b>52,783</b>	<b>4,870</b>	<b>(9,727)</b>	<b>(140,847)</b>	<b>(65)</b>	<b>1,202,109</b>

Consolidated	Balance at 12/31/2022	Business combination	Additions	Renegotiations	Amortizations	Write-offs	Balance at 06/30/2023
Properties	908,678	221,724	40,289	21,597	(81,903)	(25,472)	1,084,913
Machinery and equipment	86,683	83,568	45,855	1,153	(21,689)	(658)	194,912
IT equipment	19,103	14,203	2,078	(101)	(5,422)	(857)	29,004
Vehicles	7,823	17,302	1,422	501	(3,335)	(119)	23,594
<b>Total</b>	<b>1,022,287</b>	<b>336,797</b>	<b>89,644</b>	<b>23,150</b>	<b>(112,349)</b>	<b>(27,106)</b>	<b>1,332,423</b>

## 12. Suppliers

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
Direct material and test intermediation	118,369	76,597	340,364	242,639
Medical services	65,364	60,733	114,900	109,598
Outsourced services	18,534	18,844	46,862	53,162
Real estate and utilities	38,460	37,102	45,645	62,627
General expenses	13,215	12,041	44,416	25,154
Suppliers of property, plant and equipment - Capex	36,869	66,188	40,449	80,211
IT and telecommunications	17,165	18,628	27,126	30,056
Marketing	6,900	7,797	10,204	9,483
Institutional and legal matters	4,614	5,130	6,509	7,483
<b>Total</b>	<b>319,490</b>	<b>303,060</b>	<b>676,475</b>	<b>620,413</b>

### 13. Financing

The Company has supplier financing - drawee risk transaction mainly with Banco Itaú (Parent Company) with the following balances:

Changes – Parent Company	Balance at 12/31/2023	New agreements / Settlement	Balance at 06/30/2024
Supplier financing - drawee risk	10,162	4,347	14,509

In the Consolidated, changes are as follows:

Changes – Consolidated	Balance at 12/31/2023	Interest incurred	Interest paid	Amortization of principal	New agreements / Settlement	Balance at 06/30/2024
Supplier financing - drawee risk	11,690	-	-	-	7,035	18,725
FINEP	3,204	97	(92)	(382)	-	2,827
<b>Total</b>	<b>14,894</b>	<b>97</b>	<b>(92)</b>	<b>(382)</b>	<b>7,035</b>	<b>21,552</b>
<b>Current</b>	<b>12,473</b>					<b>19,513</b>
<b>Non-current</b>	<b>2,421</b>					<b>2,039</b>

(a) Refers to changes during the period, considering settlements/write-offs and new hires.

Consolidated	Balance at 12/31/2022	Business combination	Swap	Exchange-rate change	Interest incurred	Interest paid	Amortization of principal	New agreements / Settlement	Balance at 06/30/2023
Supplier financing - drawee risk	12,074	-	-	-	-	-	-	6,108	18,182
BNDES FINAME	465	-	-	-	6	(4)	(266)	-	201
Bank Credit Bill (CCB)	299	-	-	-	9	-	(210)	-	98
FINEP	-	3,694	-	-	44	(38)	(126)	-	3,574
Working capital	-	431,461	21,521	(15,184)	4,318	-	-	-	442,116
<b>Total</b>	<b>12,838</b>	<b>435,155</b>	<b>21,521</b>	<b>(15,184)</b>	<b>4,377</b>	<b>(42)</b>	<b>(602)</b>	<b>6,108</b>	<b>464,171</b>
<b>Current</b>	<b>12,838</b>								<b>463,884</b>
<b>Non-current</b>	<b>-</b>								<b>287</b>

### 14. Debentures

#### a) Balances – Parent Company

	Issue amount (R\$)	Quantity	Final maturity	Two-yearly interest	Total issued
5 <sup>th</sup> issue – 1 <sup>st</sup> series	1,000	200,000	Dec 2024	CDI + 0.90% p.a.	200,000
5 <sup>th</sup> issue – 2 <sup>nd</sup> series	1,000	300,000	Dec 2027	CDI + 1.20% p.a.	300,000
6 <sup>th</sup> issue – 1 <sup>st</sup> series	1,000	250,000	July 2025	CDI + 1.35% p.a.	250,000
6 <sup>th</sup> issue – 1 <sup>st</sup> series	1,000	375,000	July 2026	CDI + 1.50% p.a.	375,000
6 <sup>th</sup> Issue – 3 <sup>rd</sup> series	1,000	375,000	July 2028	CDI + 1.75% p.a.	375,000
7 <sup>th</sup> issue – 1 <sup>st</sup> series	1,000	350,000	Apr 2027	CDI + 1.35% p.a.	350,000
7 <sup>th</sup> issue – 2 <sup>nd</sup> series	1,000	350,000	Apr-2029	CDI + 1.55% p.a.	350,000
8 <sup>th</sup> issue – single series	1,000	500,000	Oct 2028	CDI + 1.23% p.a.	500,000
9 <sup>th</sup> issue – 1 <sup>st</sup> series (a)	1,000	500,000	May 2029	CDI + 0.55% p.a.	500,000
9 <sup>th</sup> issue – 2 <sup>nd</sup> series (a)	1,000	500,000	May 2031	CDI + 0.67% p.a.	500,000

(a) The Company placed a ninth issue of debentures public offering of simple debentures with restricted placement efforts, in two series. These debentures will be amortized in a single installment upon maturity (May 2029 for the first series and May 2031 for the second series).

The Company used the proceeds from debentures placements for working capital purposes, under its cash strategy, to extend its debt tenures and retain funds for investments and acquisitions in the coming years. The debentures issued are unsecured and not convertible into shares.

#### Changes in debentures

Brazilian Reais	12/31/2023	Release	Interest incurred	Interest paid	Amortization – Commission	06/30/2024
5 <sup>th</sup> issue – 1 <sup>st</sup> series	200,758	-	11,372	(11,357)	-	200,773
5 <sup>th</sup> issue – 2 <sup>nd</sup> series	301,165	-	17,521	(17,496)	-	301,190
6 <sup>th</sup> issue – 1 <sup>st</sup> series	266,246	-	14,800	(16,900)	-	264,146
6 <sup>th</sup> issue – 1 <sup>st</sup> series	399,649	-	22,489	(25,642)	-	396,496
6 <sup>th</sup> Issue – 3 <sup>rd</sup> series	400,114	-	22,971	(26,127)	-	396,958
7 <sup>th</sup> issue – 1 <sup>st</sup> series	358,267	-	20,743	(21,559)	-	357,451
7 <sup>th</sup> issue – 2 <sup>nd</sup> series	358,395	-	21,103	(21,917)	-	357,581
8 <sup>th</sup> issue – single series	511,431	-	29,323	(30,454)	-	510,300
9 <sup>th</sup> issue – 1 <sup>st</sup> series	-	500,000	4,578	-	-	504,578
9 <sup>th</sup> issue – 1 <sup>st</sup> series	-	500,000	4,631	-	-	504,631
Commissions (5 <sup>th</sup> , 6 <sup>th</sup> , 7 <sup>th</sup> and 8 <sup>th</sup> issue)	(1,346)	(1,598)	-	-	196	(2,748)
<b>Total</b>	<b>2,794,679</b>	<b>998,402</b>	<b>169,531</b>	<b>(171,452)</b>	<b>196</b>	<b>3,791,356</b>
<b>Current</b>	<b>295,622</b>	-	-	-	-	<b>293,475</b>
<b>Non-current</b>	<b>2,499,057</b>	-	-	-	-	<b>3,497,881</b>

The portion recognized in non-current liabilities as of June 30, 2024 (except for commissions) matured as follows:

Maturity	5 <sup>th</sup> issue 2 <sup>nd</sup> series	6 <sup>th</sup> issue 1 <sup>st</sup> series	6 <sup>th</sup> issue 2 <sup>nd</sup> series	6 <sup>th</sup> issue 3 <sup>rd</sup> series	7 <sup>th</sup> issue 1 <sup>st</sup> series	7 <sup>th</sup> issue 2 <sup>nd</sup> series	8 <sup>th</sup> issue Single series	9 <sup>th</sup> issue 1 <sup>st</sup> series	9 <sup>th</sup> issue 2 <sup>nd</sup> series	Consolidated
2025	100,000	250,000	-	-	-	-	-	-	-	350,000
2026	100,000	-	375,000	-	-	-	-	-	-	475,000
2027	100,000	-	-	-	350,000	-	250,000	-	-	700,000
2028	-	-	-	375,000	-	-	250,000	250,000	-	875,000
2029	-	-	-	-	-	350,000	-	250,000	-	600,000
2030	-	-	-	-	-	-	-	-	250,000	250,000
2031	-	-	-	-	-	-	-	-	250,000	250,000
<b>Total</b>	<b>300,000</b>	<b>250,000</b>	<b>375,000</b>	<b>375,000</b>	<b>350,000</b>	<b>350,000</b>	<b>500,000</b>	<b>500,000</b>	<b>500,000</b>	<b>3,500,000</b>

#### Covenants

The debentures are subject to financial covenants, and their maturity may be accelerated in the event the Company fails to comply with the following financial ratio:

- Net financial debt/EBITDA ratio lower than or equal to 3.0 times.

As of June 30, 2024, Grupo Fleury was in compliance with this financial ratio, the calculation of which is equivalent to financial leverage, as described in Note 3 (b), in addition to being in compliance with the other non-financial covenants.

#### ESG targets

The 6<sup>th</sup> issue of debentures is linked to ESG (Environmental, Social and Corporate Governance) Performance targets.

The sustainable key performance indicator ("SKPI's") must be observed on each verification date, also monitoring the targets, definitions and methods of calculation provided below:

Topic	SKPI	First Measurement	Second Measurement
		Base date 12/31/2023	Base date 12/31/2025
Biological Waste Management	Reduction of Biological Waste Generation Index	Index lower than or equal to 0.0115 kg/exam, which corresponds to a reduction of 14.12%.	Index lower than or equal to 0.0107 kg/exam, which corresponds to a reduction of 20.54%.
		Base date 06/30/2024	Base date 06/30/2026
Access to healthcare for patients from C, D and E social classes	Number of clients from social classes C, D, and E who use any DCT service from Saúde ID.	250,000 accumulated clients from these social classes.	1,000,000 accumulated clients from these social classes.

If certain targets for biological waste management and access to health are not met, as well as obligations linked to key sustainable performance indicators related to such targets are not met within the deadlines established in the Indenture, the spreads will increase by up to (i) 0.125% per annum in relation to the first series; (ii) 0.25% per annum in relation to the second series; and (iii) 0.35% per annum regarding the Third Series.

As of June 30, 2024, the Fleury Group is in compliance and there are no indications that these targets will not be met in the next measurements.

The other information referring to this Note did not undergo significant changes in relation to that disclosed in Note 14 - Debentures, of the financial statements for the year ended December 31, 2023.

## 15. Leases

As of June 30, 2024, the lease liabilities are as follows:

### a) Minimum lease payments:

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
≤01 year	245,917	250,797	391,568	390,538
>01 year	1,105,425	1,206,409	1,525,068	1,667,407
	<b>1,351,342</b>	<b>1,457,206</b>	<b>1,916,636</b>	<b>2,057,945</b>
(-) Future financial charges	(467,811)	(506,890)	(574,034)	(626,469)
<b>Present value of minimum payments</b>	<b>883,531</b>	<b>950,316</b>	<b>1,342,602</b>	<b>1,431,476</b>
<b>Current</b>	<b>171,205</b>	<b>169,531</b>	<b>280,827</b>	<b>272,067</b>
<b>Non-current</b>	<b>712,326</b>	<b>780,785</b>	<b>1,061,775</b>	<b>1,159,409</b>

The non-current portion matures as of June 30, 2024 are as follows:

	Parent Company	Consolidated
2025	110,776	161,029
2026	456,824	565,102
>2027	144,726	335,644
<b>Total</b>	<b>712,326</b>	<b>1,061,775</b>

Below are the changes in lease balances:



	Parent Company	Consolidated
Balance at 12/31/2023	950,316	1,431,476
Realization of adjustment to present value	44,263	63,434
New agreements	14,759	52,783
Indexation accrual	2,566	4,869
Write-off	(2,116)	(10,341)
Amortization of interest	(44,263)	(63,434)
Amortization of principal	(81,994)	(136,375)
Other changes	-	190
<b>Balance at 06/30/2024</b>	<b>883,531</b>	<b>1,342,602</b>

#### b) Discount rate:

The weighted average discount rates applied to lease contracts as of June 30, 2024 are shown below:

	Rates p.a.
Term of the agreements	Consolidated
01–05 years	7.58%
06–10 years	8.16%
>10 years	8.20%

#### c) Impact on income (loss) for the period:

	Parent Company		Consolidated	
	06/30/2024	06/30/2023	06/30/2024	06/30/2023
Depreciation of right-of-use	85,614	85,125	140,847	112,349
Appropriation of interest of leases	44,263	49,143	63,434	58,817
Income (loss) from write-off in the period	1,389	4,414	614	4,378

### 16. Labor obligations

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
Provision for vacation and social security charges	85,828	82,221	147,725	140,649
Provision for 13 <sup>th</sup> salary payable and charges	30,884	-	51,971	-
Salaries and social security charges payable	30,435	27,599	51,421	48,505
Provision for profit sharing	29,893	55,740	44,368	78,553
Commission and Bonus	20,715	33,617	23,386	36,632
Provision for health care	16,493	16,552	16,452	16,521
Provision for overtime	4,353	7,698	7,847	10,491
Other	1,824	3,078	9,781	7,638
<b>Total</b>	<b>220,425</b>	<b>226,505</b>	<b>352,951</b>	<b>338,989</b>

## 17. Obligations and tax installments

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
ISS on turnover	22,631	18,667	43,666	36,637
Installment Payment - ISS (a)	2,527	-	11,480	738
PIS/COFINS on Billing	1,883	660	8,344	6,824
PIS, COFINS, CSRF	3,039	2,859	5,092	4,782
REFIS installment plan - Law 11941	2,444	3,871	4,674	20,626
WITHHOLDING INCOME TAX (IRRF)	1,424	1,431	2,620	2,666
Withholding INSS	858	976	1,114	1,215
Other	1,459	1,533	2,476	2,457
<b>Total</b>	<b>36,265</b>	<b>29,997</b>	<b>79,466</b>	<b>75,945</b>
<b>Current</b>	<b>34,853</b>	<b>28,522</b>	<b>75,872</b>	<b>63,016</b>
<b>Non-current</b>	<b>1,412</b>	<b>1,475</b>	<b>3,594</b>	<b>12,929</b>

(a) The Company joined the 2024 Tax Incentive Payment Installment Program of the city of São Paulo, established by Law 18095/24 (Arts.16–26) and regulated by Decree 63341/24, opting for cash settlement of debts in July 2024.

As of June 30, 2024, the non-current portion matures as follows:

	Consolidated
2025	2,820
2026	387
>2027	387
<b>Total</b>	<b>3,594</b>

## 18. Accounts payable – Acquisition of companies

Relates to obligations assumed on acquisition of companies, to be settled as provided for in the contracts, updated monthly mainly based on IGP-M FGV and IPCA IBGE.

The balances are recorded at present value and therefore may differ from the amounts in the acquisition documents.

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
SAHA	-	-	105,221	100,606
Marcelo Magalhães	38,386	36,440	38,386	36,440
Vita	-	-	21,980	20,645
Diagmax (a)	20,502	19,429	20,502	19,429
LPA	-	-	17,522	16,653
CIP	16,628	15,803	16,628	15,803
Moacir	-	-	12,473	11,854
Lafe (a)	-	-	11,605	23,324
Bioclinico	-	-	11,111	10,560
CSV	-	-	10,625	10,588
Pretti	-	-	9,132	8,679
APC	-	-	8,783	8,276
IACS	-	-	8,585	69,325
Others (a)	7,224	9,588	35,511	45,491
<b>Total</b>	<b>82,740</b>	<b>81,260</b>	<b>328,064</b>	<b>397,673</b>
<b>Current</b>	<b>1,821</b>	<b>4,529</b>	<b>15,876</b>	<b>31,097</b>
<b>Non-current</b>	<b>80,919</b>	<b>76,731</b>	<b>312,188</b>	<b>366,576</b>

(a) Includes R\$ 54,431 withheld from the sellers as an escrow deposit, classified as securities (Note 4).

Changes in obligations for purchase of investments are as follows:

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
Opening balance	81,260	88,428	397,673	316,664
Liabilities from acquired companies	-	-	-	197,673
Indexation accrual	4,255	8,429	34,121	33,903
Acquisitions of companies	-	45,984	-	22,052
Payments	(2,769)	(53,195)	(98,738)	(126,265)
Other	(6)	(8,386)	(4,992)	(46,354)
<b>Total</b>	<b>82,740</b>	<b>81,260</b>	<b>328,064</b>	<b>397,673</b>

Non-current balances are shown as follows:

	Parent Company	Consolidated
2025	4,256	66,052
2026	20,502	82,207
>2027	56,161	163,929
<b>Total</b>	<b>80,919</b>	<b>312,188</b>

## 19. Other liabilities

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
Advance from clients	1,700	-	15,478	26,371
Other accounts payable	5,943	6,797	10,515	8,642
Employee reimbursements	332	360	332	377
<b>Total</b>	<b>7,975</b>	<b>7,157</b>	<b>26,325</b>	<b>35,390</b>
<b>Current</b>	<b>7,975</b>	<b>7,139</b>	<b>26,325</b>	<b>35,372</b>
<b>Non-current</b>	<b>-</b>	<b>18</b>	<b>-</b>	<b>18</b>

## 20. Current and deferred income tax and social contribution

### a) Balances

	Parent Company			Consolidated		
	Balance sheet		Income (loss)	Balance sheet		Income (loss)
	06/30/2024	12/31/2023	06/30/2024	06/30/2024	12/31/2023	06/30/2024
Tax x accounting difference - leases	36,217	34,986	1,231	49,088	46,398	2,690
Tax loss carryforwards	-	-	-	51,091	46,675	4,416
Provision for legal risks	17,826	15,556	2,270	24,553	20,397	4,156
Tax x accounting difference - depreciation	24,940	19,733	5,207	24,940	19,733	5,207
Losses on disallowances and default	16,896	7,199	9,697	24,145	13,040	11,105
Linearization of effective rate	38,507	-	38,507	38,507	-	38,507
Labor provisions	11,429	13,269	(1,840)	17,433	20,232	(2,799)
Indexation charges - Accounts payable from acquisitions	4,447	4,617	(170)	13,395	10,526	2,869
Provision for profit sharing	10,164	18,952	(8,788)	14,862	26,395	(11,533)
Provision for long-term incentives	8,651	10,563	(1,912)	8,651	10,563	(1,912)
Effects of goodwill amortization for tax purposes	(496,738)	(480,850)	(15,888)	(640,847)	(613,396)	(27,451)
Surplus (loss) on the acquisition of subsidiary	18,159	10,494	7,665	(139,111)	(146,303)	7,192
Other	(139)	32	(171)	(868)	(437)	(431)
<b>Deferred tax assets (liabilities), net</b>	<b>(309,641)</b>	<b>(345,449)</b>	<b>35,808</b>	<b>(514,161)</b>	<b>(546,177)</b>	<b>32,016</b>

Reflected on the balance sheet as follows:	Parent Company	Consolidated
Opening balance at 12/31/2023	(345,449)	(546,177)
Tax income/(expenses) recognized in income (loss)	35,808	31,987
Changes in equity not affecting income (loss)	-	29
<b>Deferred tax liabilities, net</b>	<b>(309,641)</b>	<b>(514,161)</b>

We present below the deferred taxes by company for the period ended June 30, 2024.

	Deferred income tax and social contribution		Net balance	
	Assets	Liabilities	Parent Company	Consolidated
SantéCorp Ltda.	24,594	-	-	24,594
Vita Clínicas Medicina Especializada Ltda.	2,054	-	-	2,054
Laboratório Padrão S.A.	2,211	-	-	2,211
CPC – Centro de Patologia Clínica Ltda.	1,824	-	-	1,824
Laboratório de Dr. Paulo Azevedo Ltda. (LPA)	1,124	-	-	1,124
Centro de Infusões Pacaembu Ltda. ("CIP")	795	(720)	-	75
Other companies	5,403	-	-	5,403
<b>Subtotal of deferred assets, net</b>	<b>38,005</b>	<b>(720)</b>	-	<b>37,285</b>
Fleury S.A.	171,127	(480,768)	(309,641)	(309,641)
Business combination - recorded in the investment group.	40,541	(154,498)	-	(113,957)
Instituto Hermes Pardini S.A. ("Hermes Pardini")	29,416	(117,104)	-	(87,688)
Fleury Centro de Procedimentos Médicos Avançados S.A. ("Fleury CPMA")	30,240	(70,400)	-	(40,160)
<b>Subtotal deferred tax liabilities, net</b>	<b>271,324</b>	<b>(822,770)</b>	<b>(309,641)</b>	<b>(551,446)</b>
<b>Total deferred tax assets (liabilities)</b>	<b>309,329</b>	<b>(823,490)</b>	<b>(309,641)</b>	<b>(514,161)</b>

In the Consolidated, deferred tax assets are expected to be realized as follows:

	Consolidated
≤12 months	150,825
>12 months	158,504
<b>Total</b>	<b>309,329</b>

**b) Income tax and social contribution on net income, current and deferred, in income (loss) are reconciled as follows:**

	Parent Company		Consolidated	
	06/30/2024	06/30/2023	06/30/2024	06/30/2023
Income before income tax (IRPJ) and social contribution (CSLL)	378,616	191,893	445,068	223,226
(x) Combined statutory nominal rate	34%	34%	34%	34%
<b>(=) IRPJ and CSLL expense</b>	<b>(128,729)</b>	<b>(65,244)</b>	<b>(151,323)</b>	<b>(75,897)</b>
Linearization effect of the effective rate	38,507	16,300	38,507	17,336
Effect of Company under the presumed profit tax regime	-	-	5,218	2,534
Equity in results of subsidiaries	50,280	25,025	391	87
Other permanent exclusions, net	2,871	306	2,616	580
<b>Income tax and social contribution expense</b>	<b>(37,071)</b>	<b>(23,613)</b>	<b>(104,591)</b>	<b>(55,360)</b>
<b>Current</b>	<b>(72,879)</b>	<b>(39,985)</b>	<b>(136,578)</b>	<b>(77,940)</b>
<b>Deferred</b>	<b>35,808</b>	<b>16,372</b>	<b>31,987</b>	<b>22,580</b>
<b>Effective rate - %</b>	<b>9.79%</b>	<b>12.31%</b>	<b>23.50%</b>	<b>24.80%</b>

## 21. Provision for tax, labor, civil risks

### a) Breakdown of balance

	Parent Company		Consolidated	
	06/30/2024	12/31/2023	06/30/2024	12/31/2023
Tax	22,391	20,476	39,391	33,479
Civil	9,960	5,807	31,084	24,938
Labor	20,077	19,470	24,957	23,116
<b>Subtotal</b>	<b>52,428</b>	<b>45,753</b>	<b>95,432</b>	<b>81,533</b>
Loss on lawsuits	-	-	115,020	120,612
Judicial deposits (lawsuits assessed as probable losses)	(40,683)	(39,871)	(42,751)	(40,806)
<b>Total</b>	<b>11,745</b>	<b>5,882</b>	<b>167,701</b>	<b>161,339</b>
Judicial deposits (lawsuits assessed as possible and remote losses – Classified as non-current assets)	(18,002)	(18,065)	(27,021)	(25,856)

### b) Changes – Consolidated

	Balance at 12/31/2023	Addition/Reversal	Realization of loss	Reclassifications/Payments	Indexation accrual	Balance at 06/30/2024
Tax	33,479	4,868	-	72	972	39,391
Civil	24,938	384	-	327	5,435	31,084
Labor	23,116	2,751	-	(1,946)	1,036	24,957
<b>Subtotal</b>	<b>81,533</b>	<b>8,003</b>	<b>-</b>	<b>(1,547)</b>	<b>7,443</b>	<b>95,432</b>
Loss on lawsuits	120,612	-	(7,367)	1,775	-	115,020
Judicial deposits (lawsuits assessed as probable losses)	(40,806)	-	-	(3,980)	2,035	(42,751)
<b>Total</b>	<b>161,339</b>	<b>8,003</b>	<b>(7,367)</b>	<b>(3,752)</b>	<b>9,478</b>	<b>167,701</b>

### c) Lawsuits classified as probable losses, for which no provision is set up:

#### Tax

The Company is party to tax lawsuits that amount R\$ 39,391 as of June 30, 2024 (R\$ 33,479 as of December 31, 2023), primarily a challenge of the unconstitutionality of Law 11001/2001, which introduced ICMS (state VAT) on imports in the state of São Paulo. This law was enacted after Constitutional Amendment 33/2001 and before Supplementary Law 114/2002, therefore failing to comply with the legislative procedure required for the collection of the ICMS levied on import transactions carried out in the state of São Paulo. However, considering a statement with general repercussion issued by the Federal Supreme Court, which established that Law 11001/2001 was constitutional, the Company set up a provision to cover the related risks totaling R\$ 17,323 as of June 30, 2024 (R\$ 16,981 as of December 31, 2023).

Other proceedings arising from companies acquired by Fleury S.A. in 2023, involve the discussion about IRPJ and CSLL offsetting declared in PER/DCOMPs for the years 2011 to 2022, with a provision of R\$ 3,710 as of June 30, 2024 (R\$ 3,210 as of December 31, 2023).

## Civil

The Company has lawsuits in the civil courts classified as probable losses totaling R\$ 31,084 as of June 30, 2024 (R\$ 24,938 as of December 31, 2023). Civil proceedings provisioned as a probable loss are those in which there is evidence that corroborates the probable occurrence of disbursement by the Company. Such proceedings are mostly demands.

## Labor

The Company has lawsuits in the labor courts classified as probable losses at June 30, 2024, totaling R\$ 24,957 (R\$ 23,116 as of December 31, 2023), which (i) R\$ 22,087 (R\$ 21,334 as of December 31, 2023) refers to lawsuits (such as labor claims from former employees, class actions, annulment actions); (ii) R\$ 2,405 (R\$ 1,479 as of December 31, 2023) refer to joint liability lawsuits filed by employees of companies that provide specialized services to the Company on an outsourced basis and (iii) ongoing administrative proceedings, totaling R\$ 464 (R\$ 276 as of December 31, 2023).

For the presentation of comparative figures as of December 31, 2023, we had immaterial changes.

### d) Lawsuits classified as possible losses

As of June 30, 2024, the consolidated amount was approximately R\$ 648,895 (R\$ 614,650 as of December 31, 2023).

Administrative and judicial proceedings of a tax nature classified as possible loss total R\$ 418,569 (R\$ 394,634 as of December 31, 2023) being federal taxes, social security contributions, federal taxes of a different nature, state taxes and municipal taxes.

At the Federal tax level, the judicial and administrative proceedings are: (i) federal taxes of R\$ 223,786 (R\$ 201,736 as of December 31, 2023), which mainly refer to discussions involving the non-mandatory payment of federal taxes (IRPJ, CSLL, PIS and COFINS), the most representative being a claim of R\$ 28,158 referring to the Annulment Suit filed for the waiving of the tax credit arising from an administrative proceeding filed in 2012 aiming at the collection of IRPJ, CSLL, PIS and COFINS launched by arbitration of revenues from the company NKB (merged by Fleury S.A. in August 2009). Further amounts of R\$ 71,385 from lawsuits of the companies acquired by Fleury S.A. in 2011, (ii) social security contributions, totaling R\$ 61,158 (R\$ 60,245 as of December 31, 2023), and (iii) federal taxes of a different nature, totaling R\$ 10,227 (R\$ 15,442 as of December 31, 2023).

At the State tax level, the law lawsuits classified as possible losses totaled R\$ 6,612 (R\$ 9,715 as of December 31, 2023) and relate mainly to the challenge of ICMS levied on equipment imports.

At the Municipal tax level, the lawsuits classified as possible losses amounted to R\$ 116,786 (R\$ 104,347 as of December 31, 2023) and related mainly to cases involving the Tax on Services of any Nature (ISSQN).

At the Civil level, the Company has lawsuits classified as possible loss totaling R\$ 114,255 (R\$ 116,853 as of December 31, 2023), of which R\$ 54,532 (R\$ 46,094 as of December 31, 2023) related mainly to civil liability lawsuits with claims for property damages and mental distress arising, among other reasons, from alleged

diagnostic error or procedural failure, and other lawsuits involving different claims totaling R\$ 59,723 (R\$ 70,759 as of December 31, 2023).

As of June 30, 2024, labor lawsuits classified as possible loss total R\$ 116,071 (R\$ 103,162 as of December 31, 2023) of which (i) R\$ 93,117 (R\$ 79,073 as of December 31, 2023) refer to lawsuits (such as labor claims of former employees, relief from judgment, public civil lawsuits, annulment and tax enforcement actions, enforcement action); (ii) R\$ 22,351 (R\$ 23,810 as of December 31, 2023) refer to joint liability lawsuits filed by employees of companies that provide specialized services to the Company on an outsourced basis and (iii) ongoing administrative proceedings, totaling R\$ 603 (R\$ 279 as of December 31, 2023).

### **Public civil actions**

Regarding Public Civil Actions in which the Company was mentioned and which were disclosed in Note 22 of the financial statements as of December 31, 2023, the tables continue to be monitored and there are no updates this quarter that could impact 2Q24.



## 22.Related parties

### Impacts on statement of income and balance sheet

Companies	Nature of the operation	Parent Company					
		Assets		Liabilities		Income (loss) - Income/(expense)	
		06/30/2024	12/31/2023	06/30/2024	12/31/2023	06/30/2024	06/30/2023
Companhia Brasileira de Soluções e Serviços - Visa Vale	Service provider - Benefits (Meal Voucher)	2,612	47	11,130	8,751	(66,782)	(66,398)
Bradesco Vida e Previdência S.A.	Service Provider - Benefits (Private pension)	-	-	460	409	(2,761)	(3,181)
Bradesco Saúde S.A.	Service provider - Benefits (Healthcare plan – Employees)	-	-	6,337	16,890	(38,020)	(59,760)
Banco Bradesco S.A.	Sale of payroll and financial transactions	834,956	432,288	1,700	5,152	10,371	39,185
OdontoPrev S.A.	Service provider - Benefits (Odontological plan – Employees)	-	-	296	254	(1,773)	(1,887)
CM Médicos Associados Ltda.	Service provider - Rendering of medical services	-	-	182	149	(1,090)	(1,000)
Transinc Fundo de Investimento Imobiliário - FII	Rental provider - Property lease classified under CPC 06	5,810	5,621	6,761	7,542	(555)	(781)
Harmonikos Participações e Empreendimentos Ltda.	Rental provider - Property lease classified under CPC 06	7,636	8,909	8,692	10,626	(1,094)	(1,792)
Amicabilis Participações e Empreendimentos Ltda.	Rental provider - Property lease classified under CPC 06	11,326	13,214	14,105	16,044	(1,669)	(2,645)
BSP Empreendimentos Imobiliários Ltda.	Rental provider - Property lease classified under CPC 06	187,583	192,770	199,442	201,395	(12,465)	(15,223)
Prontmed Tecnologia de Dados em Saúde	Corporate investment and Service provision (use of the digital platform)	-	-	-	-	(191)	(60)
Genesis Análises Genômicas S.A.	Processing of exams - Clinical Analysis	9,211	-	-	-	13,911	-
CPC Ltda	Processing of exams - Clinical Analysis	67	81	-	-	606	656
Fleury CPMA S.A.	Processing of exams and transfer of benefits (Healthcare plan)	883	897	-	-	5,890	7,184
IRN Ltda	Processing of exams - Clinical Analysis	-	-	-	-	-	14
Metodos Laboratorio, Análises Clínicas e Hematologia LTDA.	Processing of exams - Clinical Analysis	1	211	-	-	44	-
Instituto Hermes Pardini S.A.	Processing of exams - Clinical Analysis	693	386	-	-	4,088	-
Laboratório Pretti Ltda	Processing of exams - Clinical Analysis	13	700	-	-	129	1,751
Laboratório Bioclínico Ltda.	Processing of exams - Clinical Analysis	17	459	-	-	134	1,123
Genesis Análises Genômicas S.A.	Expense reimbursement (labor of dedicated employees)	353	-	-	-	-	-
Saude iD	Transfer of benefits (Healthcare plan – Employees)	13	25	-	-	37	441
Instituto Hermes Pardini S/A	Transfer of benefits (Healthcare plan – Employees)	23	17	-	-	43	(108)
Santecorp Holding Ltda.	Sublease and transfer of benefits (Healthcare plan – Employees)	51	85	-	-	137	415
Clinica de olhos Dr. Moacir Cunha S.A.	Sublease and expense reimbursement (labor of dedicated employees)	157	19	-	-	64	216
Fleury Centro de Procedimentos Médicos Avançados S.A.	Sublease and expense reimbursement (labor of dedicated employees)	119	-	-	-	176	-
Vita Clínicas Medicina Especializada LTDA	Sublease and expense reimbursement (labor of dedicated employees)	25	285	-	-	69	94
CIP - Centro de Infusões Pacaembu LTDA	Expense reimbursement (labor of dedicated employees)	41	75	-	-	41	94
Clinica Oftalmológica São Lucas Ltda. - Retina Clinic	Expense reimbursement (labor of dedicated employees)	52	75	-	-	41	-
Saha Centro de Infusões Ltda.	Expense reimbursement (labor of dedicated employees)	69	75	-	-	50	-
		<b>1,061,711</b>	<b>656,239</b>	<b>249,105</b>	<b>267,212</b>	<b>(90,569)</b>	<b>(101,662)</b>

Companies	Nature of the operation	Consolidated					
		Assets		Liabilities		Income (loss) - Income/(expense)	
		06/30/2024	12/31/2023	06/30/2024	12/31/2023	06/30/2024	06/30/2023
Companhia Brasileira de Soluções e Serviços - Visa Vale	Service provider - Benefits (Meal Voucher)	2,811	47	11,667	9,087	(70,003)	(68,445)
Bradesco Vida e Previdência S.A.	Service Provider - Benefits (Private pension)	-	-	468	410	(2,806)	(3,224)
Bradesco Saúde S.A.	Service provider - Benefits (Healthcare plan – Employees)	-	-	6,534	16,869	(39,202)	(60,034)
Banco Bradesco S.A.	Sale of payroll and financial transactions	1,218,187	693,917	15,478	26,371	27,577	48,564
OdontoPrev S.A.	Service provider - Benefits (Odontological plan – Employees)	-	-	307	264	(1,844)	(1,958)
CM Médicos Associados Ltda.	Service provider - Rendering of medical services	-	-	182	149	(1,090)	(1,000)
Transinc Fundo de Investimento Imobiliário - FII	Rental provider - Property lease classified under CPC 06	5,810	5,621	6,761	7,542	(555)	(781)
Harmonikos Participações e Empreendimentos Ltda.	Rental provider - Property lease classified under CPC 06	7,636	8,909	8,692	10,262	(1,094)	(1,792)
Amicabilis Participações e Empreendimentos Ltda.	Rental provider - Property lease classified under CPC 06	11,326	13,214	14,105	16,044	(1,669)	(2,645)
BSP Empreendimentos Imobiliários Ltda.	Rental provider - Property lease classified under CPC 06	187,583	192,770	199,442	201,395	(12,465)	(15,223)
AP Imobiliária Ltda.	Rental provider - Property lease classified under CPC 06	13,117	14,372	15,614	17,014	(2,025)	(707)
Azevedo e Dias Administração Patrimonial Ltda.	Rental provider - Property lease classified under CPC 06	4,340	5,242	4,854	5,780	(1,269)	(428)
Bitoliz Consultoria de imóvel Ltda.	Rental provider - Property lease classified under CPC 06	2,308	2,328	2,525	2,516	(257)	(86)
Dumont Empreendimentos Imobiliários Ltda.	Rental provider - Property lease classified under CPC 06	3,468	3,734	4,500	4,737	(496)	(167)
Empreendimentos Imobiliários Vista Alegre Ltda	Rental provider - Property lease classified under CPC 06	40,255	44,104	47,796	52,082	(6,180)	(2,162)
Paes e Alcantara Serviços Ltda.	Rental provider - Property lease classified under CPC 06	9,052	9,141	9,887	9,865	(1,007)	(337)
Villa de Migliori Participações Ltda.	Rental provider - Property lease classified under CPC 06	22,275	22,456	23,017	23,020	(2,228)	(746)
Prontmed Tecnologia de Dados em Saúde	Service provision (use of the digital platform)	-	-	-	-	(380)	(580)
		<b>1,528,168</b>	<b>1,015,855</b>	<b>371,829</b>	<b>403,407</b>	<b>(116,993)</b>	<b>(111,751)</b>

Banco Bradesco, a shareholder with an indirect ownership interest in the Company, holds a stake and/or control in companies and health plan operators with commercial relationship with the Fleury group, being amongst the largest clients. The consolidated statement of income (gross income) from these clients totaled 11% as of June 30, 2024 (15% as of June 30, 2023).

No asset and liability operations were identified, except the equity in results of subsidiaries in relation to ABPF Oncologia, whose partner is Atlântica Hospitais, an indirect subsidiary of Banco Bradesco S.A.

### a) Directors' fees and Board's remuneration

The remuneration of directors and members of Management was approved at Meeting held on April 26, 2024 and are calculated in "General and administrative expenses" caption in the statement of income.

	Parent Company	
	06/30/2024	06/30/2023
<b>Directors' fees and Board's remuneration</b>		
<b>Management</b>	<b>14,224</b>	<b>14,349</b>
Salaries, social charges and benefits	6,392	4,778
Bonus and profit sharing	4,831	5,382
Share-based payments	2,872	4,111
Post-employment benefits	129	78
<b>Board of Directors</b>	<b>5,494</b>	<b>5,244</b>
Salaries, social charges and benefits	5,494	5,244
<b>Total</b>	<b>19,718</b>	<b>19,593</b>

The Company grants post-employment benefits to its management, consisting of private pension and life insurance.

The Fleury Group remunerates its employees through profit sharing, according to the performance verified during the year versus the established goals. This remuneration is recognized as a liability and profit-sharing expense, based on a methodology that considers the estimated achievement of these goals.

The expense recognized in the Parent Company related to the profit sharing program, which includes employees and management, totaled R\$ 34,065 in the period ended June 30, 2024 (R\$ 41,825 as of June 30, 2023).

## 23.Shareholders' equity

### a) Capital

The Company has an authorized capital of R\$ 4,000,000,000 (four billion reais) in common shares as provided for in its Bylaws. The capital as of June 30, 2024, fully paid-up, is R\$ 2,762,950, represented by 547,191,026 common, registered, book-entry shares with no par value. The net amount of share capital, discounted from share-issuance expenses is R\$ 2,736,029.

## b) Statutory reserve

At the Annual and Extraordinary Shareholders' Meeting held on April 26, 2024, the allocation of the Company's income (loss) for 2023 was approved, and the amount of R\$ 84,752 was retained, previously approved by the Board of Directors and allocated to the statutory profit retention reserve, aiming to finance additional investments of fixed and working capital, in addition to the expansion and development of the activities comprising the Company's corporate purpose.

## c) Dividends paid

On March 07, 2024, the Board of Directors, *ad referendum* of the Shareholders' Meeting, approved the payment of dividends to shareholders in the gross amount of R\$ 80,536 million for the year 2023, which was made on April 01, 2024. On April 26, the Annual and Extraordinary Shareholders' Meeting ratified the approval.

## d) Treasury shares

Changes in treasury shares in the period of 2024:

	Number of shares	Average share price, net of fees and brokerage	Total amount
<b>Balance at 12/31/2023</b>	<b>2,150,089</b>	<b>18.35</b>	<b>39,462</b>
Delivery of shares - Long-term incentives	(548,802)	22.43	(12,312)
<b>Balance at 06/30/2024</b>	<b>1,601,287</b>	<b>16.96</b>	<b>27,150</b>

## 24. Employee benefits

### a) Private pension

The Company is a sponsor of the supplementary pension entity named and currently managed by Bradesco Vida e Previdência S.A. and Sul América S.A., which mainly aims at supplementing the government pension benefits. The plan is of a defined contribution nature and during the period ended June 30, 2024 the Company made contributions in the amount of R\$ 1,503 (R\$ 1,198 as of June 30, 2023), recorded in "Costs of services rendered" and "General and Administrative Expenses" and "Selling expenses".

### b) Long-term incentives

The Fleury Group offers cash and share-based remuneration plans to its executives in exchange for services as consideration of the purchase and stock options granted. Granted options fair values determined on grant date are recorded under straight-line method as expenses in income (loss) for the period during the period in which the right is acquired.

As of June 28, 2024, the market value of each share was R\$ 15.03 (R\$ 15.54 as of June 30, 2023).

		<b>2018</b>	
		<b>May 10</b>	<b>June 20</b>
<b>Balance at 12/31/2023</b>	<b>Options</b>	<b>226,875</b>	<b>29,375</b>
	Average exercise price	27.66	26.24
Expired	Options	(90,750)	(11,750)
<b>Balance at 06/30/2024</b>	<b>Options</b>	<b>136,125</b>	<b>17,625</b>

#### (i) 2016–2018 Stock options granted

These were priced based on the "Black & Scholes" model, and the significant data included in the pricing model for the fair value.

As of June 30, 2024, the Company recognized a "pro-rata" expense of R\$ 735 in General and Administrative Expenses referring to the Stock Option plan (R\$ 76 as of June 30, 2023).

The other information referring to this Note did not undergo significant changes in relation to that disclosed in Note 25 - Employee benefits, of the financial statements for the year ended December 31, 2023.

## 25. Revenue from rendering of services

<b>Parent Company</b>				
	<b>Three-month period ended June 30,</b>		<b>Six-month period ended June 30</b>	
	<b>2024</b>	<b>2023</b>	<b>2024</b>	<b>2023</b>
Gross income	1,198,437	1,081,370	2,349,682	2,162,800
Taxes	(73,169)	(66,307)	(143,382)	(132,505)
Disallowances	(17,927)	(10,706)	(38,021)	(20,132)
Rebates	(1,695)	(1,234)	(3,484)	(2,785)
<b>Net revenue</b>	<b>1,105,646</b>	<b>1,003,123</b>	<b>2,164,795</b>	<b>2,007,378</b>

<b>Consolidated</b>				
	<b>Three-month period ended June 30,</b>		<b>Six-month period ended June 30</b>	
	<b>2024</b>	<b>2023</b>	<b>2024</b>	<b>2023</b>
Gross income	2,136,902	1,784,525	4,192,481	3,114,930
Taxes	(133,194)	(109,406)	(259,846)	(190,985)
Disallowances	(22,170)	(13,470)	(43,350)	(23,149)
Rebates	(3,336)	(2,108)	(6,635)	(4,432)
<b>Net revenue</b>	<b>1,978,202</b>	<b>1,659,541</b>	<b>3,882,650</b>	<b>2,896,364</b>

The net sales for the main lines of the Company's services (Diagnostic Medicine and Integrated Medicine), is presented in Note 32 - Segment Information.

## 26. Cost of services rendered

	Parent Company			
	Three-month period ended June 30,		Six-month period ended June 30	
	2024	2023	2024	2023
Medical personnel and services	(357,633)	(353,401)	(697,035)	(696,814)
Rentals, services with occupancy and utilities	(154,301)	(141,415)	(296,884)	(281,199)
Direct material and test intermediation	(147,274)	(118,331)	(273,788)	(239,026)
Depreciation and amortization	(99,113)	(94,081)	(197,606)	(186,661)
General expenses	(2,266)	(2,147)	(3,518)	(4,223)
<b>Total</b>	<b>(760,587)</b>	<b>(709,375)</b>	<b>(1,468,831)</b>	<b>(1,407,923)</b>

	Consolidated			
	Three-month period ended June 30,		Six-month period ended June 30	
	2024	2023	2024	2023
Medical personnel and services	(593,782)	(528,450)	(1,151,954)	(943,849)
Direct material and test intermediation	(418,959)	(327,996)	(816,682)	(528,610)
Rentals, services with occupancy and utilities	(243,374)	(215,279)	(476,146)	(372,554)
Depreciation and amortization	(150,040)	(129,263)	(297,147)	(232,982)
General expenses	(4,724)	(3,454)	(8,149)	(6,599)
<b>Total</b>	<b>(1,410,879)</b>	<b>(1,204,442)</b>	<b>(2,750,078)</b>	<b>(2,084,594)</b>

## 27. General and administrative expenses

	Parent Company			
	Three-month period ended June 30,		Six-month period ended June 30	
	2024	2023	2024	2023
Personnel and benefits	(69,363)	(69,424)	(136,266)	(133,613)
Depreciation and amortization	(16,807)	(18,313)	(33,448)	(41,708)
Institutional and legal matters	(4,477)	(58,879)	(14,436)	(62,902)
Real estate and utilities	(3,866)	(4,325)	(7,456)	(10,683)
Outsourced services	(3,281)	874	(6,218)	(6,300)
IT and telecommunications	(3,044)	(6,923)	(6,118)	(8,859)
Other general and administrative expenses	(5,776)	(10,956)	(12,300)	(15,904)
<b>Total</b>	<b>(106,614)</b>	<b>(167,946)</b>	<b>(216,242)</b>	<b>(279,969)</b>

	Consolidated			
	Three-month period ended June 30,		Six-month period ended June 30	
	2024	2023	2024	2023
Personnel and benefits	(96,935)	(92,478)	(186,718)	(163,948)
Depreciation and amortization	(41,764)	(36,814)	(84,211)	(64,356)
IT and telecommunications	(22,201)	(10,064)	(43,110)	(13,887)
Institutional and legal matters	(7,505)	(58,620)	(20,087)	(65,539)
Outsourced services	(5,876)	(237)	(12,369)	(8,816)
Real estate and utilities	(6,693)	(10,488)	(12,291)	(17,886)
Other general and administrative expenses	(6,768)	(7,559)	(11,365)	(13,746)
<b>Total</b>	<b>(187,742)</b>	<b>(216,260)</b>	<b>(370,151)</b>	<b>(348,178)</b>

## 28. Selling expenses

The amounts presented below are mainly due to the Hermes Pardini operation, which significantly increased the Company's Lab-to-Lab business and, consequently, commercial efforts with partner laboratories.

	Parent Company			
	Three-month period ended June 30,		Six-month period ended June 30	
	2024	2023	2024	2023
Personnel and benefits	(2,567)	(3,026)	(4,593)	(5,361)
Marketing	(9,531)	(7,140)	(14,766)	(12,581)
Other sales	(145)	(109)	(264)	(392)
<b>Total</b>	<b>(12,243)</b>	<b>(10,275)</b>	<b>(19,623)</b>	<b>(18,334)</b>

	Consolidated			
	Three-month period ended June 30 (a)		Six-month period ended June 30	
	2024	2023	2024	2023
Personnel and benefits	(24,102)	(15,910)	(43,140)	(18,206)
Marketing	(17,304)	(16,991)	(26,584)	(23,489)
Other sales	(8,179)	(5,543)	(14,577)	(5,827)
<b>Total</b>	<b>(49,585)</b>	<b>(38,444)</b>	<b>(84,301)</b>	<b>(47,522)</b>

(a) To present comparative figures for the three months ended June 30, 2023, there was a need to reclassify the nature of expenses between administrative and commercial.

## 29. Other operating revenues (expenses), net

	Parent Company			
	Three-month period ended June 30,		Six-month period ended June 30	
	2024	2023	2024	2023
Reversal (provision) for tax, labor and civil risks	4,843	(486)	3,970	(694)
Income (loss) from disposal of investments	1,155	(50)	1,206	(4,309)
Income (loss) in write-off/sale of assets	(4,609)	(414)	(4,455)	14
Provision/losses with defaulted parties	30	(688)	(9,386)	(1,502)
Other income (expenses)	(2,953)	2,089	(7,708)	1,423
<b>Total</b>	<b>(1,534)</b>	<b>451</b>	<b>(16,373)</b>	<b>(5,068)</b>

	Consolidated			
	Three-month period ended June 30,		Six-month period ended June 30	
	2024	2023	2024	2023
Income (loss) from disposal of investments	1,155	(457)	766	(503)
Reversal (provision) for tax, labor and civil risks	753	(309)	(636)	(562)
Income (loss) in write-off/sale of assets	(4,510)	(42)	(4,740)	420
Provision/losses with defaulted parties	(1,554)	(1,433)	(14,528)	(3,037)
Other income (expenses)	4,404	(652)	(1,159)	(368)
<b>Total</b>	<b>248</b>	<b>(2,893)</b>	<b>(20,297)</b>	<b>(4,050)</b>



### 30. Financial income (expense)

	Parent Company			
	Three-month period ended June 30,		Six-month period ended June 30	
	2024	2023	2024	2023
<b>Financial income:</b>				
Yield from interest earning bank deposits	24,661	26,287	42,880	63,141
Indexation accrual of taxes and judicial deposits	2,317	2,263	5,277	4,108
Exchange-rate change	56	36	82	108
Taxes on financial income and others	(421)	(1,189)	(1,074)	(2,645)
<b>Total</b>	<b>26,613</b>	<b>27,397</b>	<b>47,165</b>	<b>64,712</b>
<b>Financial expenses:</b>				
Interest on debentures	(88,472)	(81,210)	(169,531)	(170,334)
Lease interest	(21,711)	(24,305)	(44,263)	(48,981)
Indexation accrual of taxes and accounts payable	(1,141)	(2,285)	(3,501)	(5,700)
Indexation accrual of lawsuits	(1,911)	(1,168)	(7,801)	(2,662)
Exchange-rate change	(78)	(98)	(130)	(167)
Derivative financial instruments	36	(485)	104	(943)
Other	(3,527)	(1,704)	(5,290)	(4,411)
<b>Total</b>	<b>(116,804)</b>	<b>(111,255)</b>	<b>(230,412)</b>	<b>(233,198)</b>
<b>Net financial income (expense)</b>	<b>(90,191)</b>	<b>(83,858)</b>	<b>(183,247)</b>	<b>(168,486)</b>

	Consolidated			
	Three-month period ended June 30,		Six-month period ended June 30	
	2024	2023	2024	2023
<b>Financial income:</b>				
Yield from interest earning bank deposits	36,493	37,517	65,726	81,587
Indexation accrual of taxes and judicial deposits	3,152	3,064	8,709	5,152
Other	1,239	1,587	4,408	2,479
Exchange-rate change	153	18,584	192	18,656
PIS/COFINS on financial income	(1,824)	(1,873)	(3,356)	(3,988)
<b>Total</b>	<b>39,213</b>	<b>58,879</b>	<b>75,679</b>	<b>103,886</b>
<b>Financial expenses:</b>				
Interest on debentures	(88,472)	(81,210)	(169,531)	(170,333)
Lease interest	(31,232)	(26,975)	(63,434)	(58,817)
Indexation accrual of taxes and accounts payable	(11,670)	(5,913)	(31,343)	(18,356)
Indexation accrual of lawsuits	(2,436)	(1,433)	(9,567)	(3,225)
Interest on financing and other interest	(1,162)	(5,543)	(2,131)	(5,716)
Exchange-rate change	(237)	(3,419)	(345)	(3,488)
Derivative financial instruments	36	(22,006)	104	(22,464)
Other	(5,370)	(11,890)	(11,037)	(10,536)
<b>Total</b>	<b>(140,543)</b>	<b>(158,389)</b>	<b>(287,284)</b>	<b>(292,935)</b>
<b>Net financial income (expense)</b>	<b>(101,330)</b>	<b>(99,510)</b>	<b>(211,605)</b>	<b>(189,049)</b>

### 31. Earnings per share - Parent Company

Basic earnings per share is calculated by dividing profit attributable to company shareholders by the weighted average number of common shares issued during the period.

Diluted earnings per share are calculated by adjusting the weighted average number of common shares, presuming the conversion of all the potential diluted common shares.

The Company had potentially dilutable common shares due to the stock option plan.

	<b>Parent Company</b>	
	<b>06/30/2024</b>	<b>06/30/2023</b>
Income attributable to Company's controlling shareholders	341,545	168,280
Weighted average number of common shares outstanding (-) treasury shares	545,429,057	421,308,006
<b>Basic earnings per share – R\$</b>	<b>0.63</b>	<b>0.40</b>
(+) Adjustment by stock options	27,829	72,150
<b>(=) Weighted average of number of common shares for diluted earnings per share</b>	<b>545,456,886</b>	<b>421,380,156</b>
<b>Diluted earnings per share - R\$</b>	<b>0.63</b>	<b>0.40</b>

### 32. Information per business segment

As of June 30, 2024, the Fleury Group's Management conducts its analyses based on two reportable business segments: Diagnostic Medicine and Integrated Medicine. The segments presented in the financial statements are strategic business units that offer different products and services.

	<b>Period ended 06/30/2024</b>		
	<b>Diagnostic medicine</b>	<b>Integrated medicine</b>	<b>Consolidated</b>
Net revenue	2,605,091	1,277,559	3,882,650
<b>EBITDA</b>	<b>886,099</b>	<b>153,082</b>	<b>1,039,181</b>
Equity in results of subsidiaries	-	(1,150)	(1,150)
Depreciation and amortization	-	-	(381,358)
Financial income (expense)	-	-	(211,605)
<b>EBIT</b>	<b>-</b>	<b>-</b>	<b>445,068</b>

	<b>Period ended 06/30/2023</b>		
	<b>Diagnostic medicine</b>	<b>Integrated medicine</b>	<b>Consolidated</b>
Net revenue	2,145,662	750,702	2,896,364
<b>EBITDA</b>	<b>656,641</b>	<b>52,716</b>	<b>709,357</b>
Equity in results of subsidiaries	-	255	255
Depreciation and amortization	-	-	(297,338)
Financial income (expense)	-	-	(189,049)
<b>EBIT</b>	<b>-</b>	<b>-</b>	<b>223,226</b>

### 33. Insurance coverage

The Company takes out insurance for potential risks related to its assets, loss of profits and/or liabilities in amounts sufficient to cover possible claims (unaudited), considering the nature of its activities and in accordance

with the assessment of Management and its specialized consultants. The full premium of the consolidated insurance policies in effect as of June 30, 2024 is R\$ 5,254. The contracts are effective until April 12, 2025.

The maximum insured amount of the main insurance coverages, as of June 30, 2024, is as follows:

	<b>Consolidated</b>
Operational risks	792,959
Civil liability, including cyber risks	182,000
International transport – Imports - US\$	750

\*\*\*\*\*

Jeane Tsutsui  
CEO

José Antônio de Almeida Filippo  
Chief Financial, Legal and Investor Relations Officer

Gisele Schneider  
Accountant  
CRC 1SP304488